{ "$schema_version": "5.3", "review_mode": "fresh", "claim_restatement": { "index_wording": "Metabolic / 'Type 3 Diabetes' Hypothesis", "entry_form": "phenomenon", "gradeable_restatement": "Primary dysfunction of neuronal insulin/IGF-1 signalling initiates and drives sporadic Alzheimer's disease, and correcting this dysfunction modifies the disease trajectory.", "restatement_required": true, "split_into": [], "parent_claim": null, "scope_qualifiers": [ { "qualifier": "Sporadic rather than familial AD; neuronal rather than peripheral or glial signalling; prelesion stage; baseline amyloid confirmation and delivery regimen fixed in advance", "determinable_before_outcome": true, "determined_from": "Enrollment and experimental design, before results; no responder-defined scope.", "action": "retained" } ] }, "hypothesis": { "name": "Metabolic / 'Type 3 Diabetes' Hypothesis", "central_claim": "Primary dysfunction of neuronal insulin/IGF-1 signalling initiates and drives sporadic Alzheimer's disease, and correcting this dysfunction modifies the disease trajectory.", "proposed_mechanism": "Primary dysfunction of neuronal insulin/IGF-1 signalling initiates and drives sporadic Alzheimer's disease, and correcting this dysfunction modifies the disease trajectory.", "claimed_scope": "Primary dysfunction of neuronal insulin/IGF-1 signalling initiates and drives sporadic Alzheimer's disease, and correcting this dysfunction modifies the disease trajectory.", "claimed_level": [ "initiation", "progression", "clinical disease modification" ], "is_conjunctive": true, "conjunctive_note": "Retain the exact index primary metabolic rubric with co-governing neurodegeneration rules. Presence, causal contribution, upstream primacy and clinical application are scored separately; the conjunctive wording takes the weakest link, with direction and treatment sensitivities displayed. Neither FDG deficit nor peripheral diabetes alone establishes neuronal insulin resistance." }, "rubric_routing": { "primary_rubric": "06-metabolism-aging.md", "secondary_rubrics": [ "01-neurodegeneration.md" ], "index_notes_applied": [ "Retain the exact index primary metabolic rubric with co-governing neurodegeneration rules. Presence, causal contribution, upstream primacy and clinical application are scored separately; the conjunctive wording takes the weakest link, with direction and treatment sensitivities displayed. Neither FDG deficit nor peripheral diabetes alone establishes neuronal insulin resistance." ], "rubric_fit_note": "Exact archived v5.3 framework. Any stale index empirical framing is rechecked against primary results." }, "subclaim_matrix": { "subclaims": [ { "id": "SC1", "statement": "Brain insulin resistance is present independently of peripheral type2 diabetes.", "subclaim_type": "existence", "scope": "sporadic AD brains and matched controls", "claimed_scope": "sporadic AD brains and matched controls", "governing_rubric": "06-metabolism-aging.md", "key_evidence_anchor": "Ex-vivo insulin-response analysis with cell and vascular controls", "hsef_level": "Γ", "confidence": "Moderate", "governing_cap_or_threshold": "Quoted boundary and upward audit below.", "rationale": "Functional postmortem challenge supports insulin/IGF resistance in selected AD hippocampal samples without diabetes, beyond static marker abundance. Other region/site assays are null or show higher downstream AKT activity. Γ records support for this finding within the causal review; it does not deny the observed functional resistance. No disease-trajectory crossing is inferred from tissue responsiveness alone." }, { "id": "SC2", "statement": "Failure of neuronal insulin signaling contributes causally to AD pathology.", "subclaim_type": "mechanism", "scope": "defined neuronal and AD disease contexts", "claimed_scope": "defined neuronal and AD disease contexts", "governing_rubric": "06-metabolism-aging.md", "key_evidence_anchor": "Selective pathway loss/rescue and functional trajectory", "hsef_level": "Ε", "confidence": "Moderate", "governing_cap_or_threshold": "Quoted boundary and upward audit below.", "rationale": "Loss, rescue and pathway support affect synaptic or cognitive function in defined models, reaching constrained causal contribution. Adult glial deletions demonstrate cell-type differences and neuronal PTP1B/GLP1 manipulations protect disease-model function. The IR and IGF branches cannot be merged: neuronal IGF attenuation can instead be protective, and selective adult neuronal IR mediation remains incompletely isolated." }, { "id": "SC3", "statement": "Neuronal insulin resistance is upstream of amyloid and tau.", "subclaim_type": "primacy", "scope": "sporadic human preclinical initiation", "claimed_scope": "sporadic human preclinical initiation", "governing_rubric": "06-metabolism-aging.md", "key_evidence_anchor": "Temporal mediation and early selective intervention", "hsef_level": "Γ", "confidence": "Moderate", "governing_cap_or_threshold": "Quoted boundary and upward audit below.", "rationale": "Primary upstream failure remains a mechanistic possibility supported by imposed metabolic injury and antecedent peripheral/putative EV clues, but no selective neuronal instrument or serial preamyloid/tau functional assay establishes sporadic human order. Models demonstrate the opposite direction as well. Γ is an unmet positive primacy burden, not a blanket observational cap imposed on the entire convergent set." }, { "id": "SC4", "statement": "Insulin-targeting therapy modifies clinical disease trajectory.", "subclaim_type": "application", "scope": "prespecified AD/MCI populations and clinical horizons", "claimed_scope": "prespecified AD/MCI populations and clinical horizons", "governing_rubric": "06-metabolism-aging.md", "key_evidence_anchor": "Adequately powered target-engaged randomized outcomes", "hsef_level": "Γ", "confidence": "Moderate", "governing_cap_or_threshold": "Quoted boundary and upward audit below.", "rationale": "Small insulin/metformin and recent short factorial trials show scoped clinical signals, but larger insulin, rosiglitazone, pioglitazone and GLP1 trials do not establish reproducible disease modification. SNIFF delivery uncertainty and pleiotropic/systemic engagement prevent interpreting failed regimens as a universal negative neuronal mechanism test. ELAD secondary cognition is unadjusted and EVOKE clinical outcomes are null." } ], "aggregation_rule": "weakest-link", "aggregation_preregistered": true, "aggregation_rationale": "Retain the exact index primary metabolic rubric with co-governing neurodegeneration rules. Presence, causal contribution, upstream primacy and clinical application are scored separately; the conjunctive wording takes the weakest link, with direction and treatment sensitivities displayed. Neither FDG deficit nor peripheral diabetes alone establishes neuronal insulin resistance.", "primary_subclaim_id": "SC3", "aggregation_derivation": "Γ follows the preregistered weakest-link bundle (Γ,Ε,Γ,Γ); primary-SC3 and scope-matched sensitivities also return Γ. Model-specific causal contribution earns Ε, while primary sporadic neuronal initiation and clinically proven correction remain unestablished. Functional tissue resistance, acute memory effects, peripheral prevention and FDG changes are kept distinct. Positive models and valid human causal equivalents are assessed together, without automatically re-capping their weaker observational members.", "aggregation_alternatives": { "weakest_link_would_return": "Γ", "primary_subclaim_would_return": "Γ", "scope_matched_would_return": "Γ", "note": "Separate narrow successes do not replace the preregistered gate." }, "index_rule_deviation": "" }, "competing_models": { "models_evaluated": [ { "rank_in_tournament": 1, "model_id": "M2", "is_nominal": false, "name": "Amyloid/tau-induced resistance with feedback", "core_claim": "AD-related injury can disrupt insulin-related signalling, which can amplify subsequent dysfunction.", "explains_what_nominal_does_not": "AD-related injury can disrupt insulin-related signalling, which can amplify subsequent dysfunction.", "strongest_supporting_evidence": [ "Oligomer induction, TNFR1/PKR intervention, tau deletion and insulin/GLP1 rescue establish direction and contribution in defined systems (PMID22476196,24315369,28652303)." ], "strongest_contradictory_evidence": [ "Sole temporal ordering and neuronal mediation in sporadic humans remain unproved." ], "hsef_level_for_this_model": "Ε", "rationale": "Oligomer induction, TNFR1/PKR intervention, tau deletion and insulin/GLP1 rescue establish direction and contribution in defined systems (PMID22476196,24315369,28652303). Sole temporal ordering and neuronal mediation in sporadic humans remain unproved." }, { "rank_in_tournament": 2, "model_id": "M5", "is_nominal": false, "name": "Permissive neurotrophic support", "core_claim": "Insulin-related signalling supports synapses and memory without constituting a primary AD trigger.", "explains_what_nominal_does_not": "Insulin-related signalling supports synapses and memory without constituting a primary AD trigger.", "strongest_supporting_evidence": [ "IR dosage changes and normal-human memory modulation show functional support; NIRKO markers without degeneration separate vulnerability from initiation (PMID22661254,15288712,14981233)." ], "strongest_contradictory_evidence": [ "Adult neuron-specific necessity in AD is not established, and IGF-reduction protection requires branch-specific explanation." ], "hsef_level_for_this_model": "Ε", "rationale": "IR dosage changes and normal-human memory modulation show functional support; NIRKO markers without degeneration separate vulnerability from initiation (PMID22661254,15288712,14981233). Adult neuron-specific necessity in AD is not established, and IGF-reduction protection requires branch-specific explanation." }, { "rank_in_tournament": 3, "model_id": "M4", "is_nominal": false, "name": "Neurovascular/peripheral metabolic contribution", "core_claim": "Metabolic risk can act through systemic and vascular routes without primary neuronal receptor failure.", "explains_what_nominal_does_not": "Metabolic risk can act through systemic and vascular routes without primary neuronal receptor failure.", "strongest_supporting_evidence": [ "Diabetes incidence cohorts, brain-infarct associations, peripheral sensitivity MR and ancillary randomized dementia contrasts fit this route (PMID10599761,33858515,39479764,35229024)." ], "strongest_contradictory_evidence": [ "The particular mediator remains unidentified and diabetes-liability MR is null in several tests." ], "hsef_level_for_this_model": "Γ", "rationale": "Diabetes incidence cohorts, brain-infarct associations, peripheral sensitivity MR and ancillary randomized dementia contrasts fit this route (PMID10599761,33858515,39479764,35229024). The particular mediator remains unidentified and diabetes-liability MR is null in several tests." }, { "rank_in_tournament": 4, "model_id": "M3", "is_nominal": false, "name": "Reduced synaptic demand and secondary glucose change", "core_claim": "Loss of synapses/cells or altered transport can produce FDG and tissue-glucose abnormalities.", "explains_what_nominal_does_not": "Loss of synapses/cells or altered transport can produce FDG and tissue-glucose abnormalities.", "strongest_supporting_evidence": [ "BLSA glucose/GLUT3 and Talbot glucose-uptake controls distinguish metabolic readouts from peripheral-style insulin-dependent uptake (PMID29055815,22476197)." ], "strongest_contradictory_evidence": [ "These observations do not themselves isolate a demand-only cause or exclude signalling feedback." ], "hsef_level_for_this_model": "Γ", "rationale": "BLSA glucose/GLUT3 and Talbot glucose-uptake controls distinguish metabolic readouts from peripheral-style insulin-dependent uptake (PMID29055815,22476197). These observations do not themselves isolate a demand-only cause or exclude signalling feedback." }, { "rank_in_tournament": 5, "model_id": "M1", "is_nominal": true, "name": "Primary neuronal insulin/IGF failure", "core_claim": "A native neuronal signalling defect precedes and drives sporadic AD, and correcting it modifies clinical trajectory.", "explains_what_nominal_does_not": "A native neuronal signalling defect precedes and drives sporadic AD, and correcting it modifies clinical trajectory.", "strongest_supporting_evidence": [ "Functional postmortem resistance, induced metabolic injury and small therapeutic signals provide the strongest case." ], "strongest_contradictory_evidence": [ "Native prelesion ordering is absent; IR deletion need not produce degeneration, IGF attenuation can protect, and large clinical correction predictions fail." ], "hsef_level_for_this_model": "Γ", "rationale": "Functional postmortem resistance, induced metabolic injury and small therapeutic signals provide the strongest case. Native prelesion ordering is absent; IR deletion need not produce degeneration, IGF attenuation can protect, and large clinical correction predictions fail." } ], "tournament_summary": "Descriptive comparison; does not modify the nominal score. A selective adult neuronal IR perturbation/rescue with verified live target engagement, repeated prelesion amyloid/tau measures and long-term function separates primary failure from feedback or permissive support. Branch, cell type and systemic effects must be identified independently.", "study_separating_rank1_from_rank2": "A selective adult neuronal IR perturbation/rescue with verified live target engagement, repeated prelesion amyloid/tau measures and long-term function separates primary failure from feedback or permissive support. Branch, cell type and systemic effects must be identified independently.", "nominal_wins_only_by_funding_artifact": false, "level_unchanged_by_tournament": true }, "evidence_inventory": [ { "n": 1, "pmid": "15750215", "title": "Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes?", "citation": "Steen E, Terry BM, Rivera EJ et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes? Journal of Alzheimer's disease : JAD. 2005.", "doi": "10.3233/jad-2005-7107", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/15750215/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/15750215/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID15750215", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC3" ], "favors_models": [], "evidence_class": "Weak", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "AD postmortem brains show lower insulin/IGF pathway expression and altered survival-signalling markers, motivating the type3-diabetes framing.", "what_it_does_not_show": "Terminal expression and cell-composition changes do not establish an initiating neuronal endocrine defect or temporal direction.", "confounders_present": [ "Terminal expression and cell-composition changes do not establish an initiating neuronal endocrine defect or temporal direction." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 2, "pmid": "22476197", "title": "Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline.", "citation": "Talbot K, Wang HY, Kazi H et al. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. The Journal of clinical investigation. 2012.", "doi": "10.1172/JCI59903", "pmcid": "PMC3314463", "url": "https://pubmed.ncbi.nlm.nih.gov/22476197/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/22476197/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID22476197", "access_depth": "full_text_partial", "access_note": "Complete primary abstract and linked-status metadata examined. Selected body sections: Results:ex-vivo validation and glucose uptake; Methods:Subjects, tissue preparation, insulin stimulation. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "human ex-vivo", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "AD hippocampal tissue without diabetes responds less to insulin and IGF challenge; IRS1 serine measures associate with cognition and pathology.", "what_it_does_not_show": "Original Methods validate low-PMI tissue and insulin dose responses, but peripheral IR data were unavailable. Original Results find no basal glucose-uptake response to insulin in either group, with glutamate as a positive control. Functional postmortem resistance does not order it before amyloid/tau or establish trajectory benefit.", "confounders_present": [ "Original Methods validate low-PMI tissue and insulin dose responses, but peripheral IR data were unavailable. Original Results find no basal glucose-uptake response to insulin in either group, with glutamate as a positive control. Functional postmortem resistance does not order it before amyloid/tau or establish trajectory benefit." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [ "UPenn and ROS archives; overlap with other ROS analyses may exist, without assuming identical 150-person samples." ] }, { "n": 3, "pmid": "32557841", "title": "Brain Insulin Signaling, Alzheimer Disease Pathology, and Cognitive Function.", "citation": "Arvanitakis Z, Wang HY, Capuano AW et al. Brain Insulin Signaling, Alzheimer Disease Pathology, and Cognitive Function. Annals of neurology. 2020.", "doi": "10.1002/ana.25826", "pmcid": "PMC7722192", "url": "https://pubmed.ncbi.nlm.nih.gov/32557841/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/32557841/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "ROS-150-matched-brains", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "human ex-vivo", "decisive_perturbation": true, "endogenous": false, "direction": "null", "what_it_shows": "In 150 matched ROS brains, IRS1 measures and ex-vivo response were not associated with global AD pathology; higher AKT phosphorylation was associated with pathology and lower cognition.", "what_it_does_not_show": "Different region, phosphorylation site and assay prevent a simple exact replication claim; AKT integrates other growth-factor signals and tissue was obtained after disease.", "confounders_present": [ "Different region, phosphorylation site and assay prevent a simple exact replication claim; AKT integrates other growth-factor signals and tissue was obtained after disease." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 4, "pmid": "38029396", "title": "Brain Insulin Signaling is Associated with Late-Life Cognitive Decline.", "citation": "Tong H, Capuano AW, Carmichael OT et al. Brain Insulin Signaling is Associated with Late-Life Cognitive Decline. Aging and disease. 2024.", "doi": "10.14336/AD.2023.1117", "pmcid": "PMC11346412", "url": "https://pubmed.ncbi.nlm.nih.gov/38029396/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/38029396/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "ROS-150-matched-brains", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC3" ], "favors_models": [], "evidence_class": "Weak", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "contradicts", "what_it_shows": "In the same 150 ROS individuals, higher terminal AKT phosphorylation tracked faster prior cognitive decline; IRS1 signals were largely null.", "what_it_does_not_show": "Longitudinal cognition with a terminal pathway assay is not longitudinal neuronal insulin measurement; this is shared-cohort follow-up rather than independent replication.", "confounders_present": [ "Longitudinal cognition with a terminal pathway assay is not longitudinal neuronal insulin measurement; this is shared-cohort follow-up rather than independent replication." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 5, "pmid": "25107476", "title": "Abnormal serine phosphorylation of insulin receptor substrate 1 is associated with tau pathology in Alzheimer's disease and tauopathies.", "citation": "Yarchoan M, Toledo JB, Lee EB et al. Abnormal serine phosphorylation of insulin receptor substrate 1 is associated with tau pathology in Alzheimer's disease and tauopathies. Acta neuropathologica. 2014.", "doi": "10.1007/s00401-014-1328-5", "pmcid": "PMC4304658", "url": "https://pubmed.ncbi.nlm.nih.gov/25107476/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/25107476/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID25107476", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC3" ], "favors_models": [], "evidence_class": "Weak", "system": "human observational and transgenic mouse", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "IRS1 serine phosphorylation occurs in AD and other tauopathies; tau transgenics and high-fat diet link it with abnormal tau.", "what_it_does_not_show": "Disease specificity and direction are unresolved; abnormal tau can precede the marker and diet affects several metabolic routes.", "confounders_present": [ "Disease specificity and direction are unresolved; abnormal tau can precede the marker and diet affects several metabolic routes." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 6, "pmid": "29055815", "title": "Evidence for brain glucose dysregulation in Alzheimer's disease.", "citation": "An Y, Varma VR, Varma S et al. Evidence for brain glucose dysregulation in Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2018.", "doi": "10.1016/j.jalz.2017.09.011", "pmcid": "PMC5866736", "url": "https://pubmed.ncbi.nlm.nih.gov/29055815/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/29055815/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID29055815", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC3" ], "favors_models": [], "evidence_class": "Weak", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "BLSA autopsies link higher tissue glucose, lower glycolytic flux and GLUT3 with AD severity; prior plasma glucose relates to tissue glucose.", "what_it_does_not_show": "Glucose accumulation and predominantly insulin-independent transport do not diagnose neuronal insulin resistance; preclinical symptoms are not prelesion order.", "confounders_present": [ "Glucose accumulation and predominantly insulin-independent transport do not diagnose neuronal insulin resistance; preclinical symptoms are not prelesion order." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 7, "pmid": "33597002", "title": "Does insulin resistance influence neurodegeneration in non-diabetic Alzheimer's subjects?", "citation": "Femminella GD, Livingston NR, Raza S et al. Does insulin resistance influence neurodegeneration in non-diabetic Alzheimer's subjects? Alzheimer's research & therapy. 2021.", "doi": "10.1186/s13195-021-00784-w", "pmcid": "PMC7890851", "url": "https://pubmed.ncbi.nlm.nih.gov/33597002/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33597002/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID33597002", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC3" ], "favors_models": [], "evidence_class": "Weak", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Peripheral HOMA2 associates with lower hippocampal FDG metabolism and total grey matter in 130 nondiabetic AD participants.", "what_it_does_not_show": "HOMA2 measures peripheral resistance, not neuronal response; cross-sectional FDG and volume do not identify initiation or causal mediation.", "confounders_present": [ "HOMA2 measures peripheral resistance, not neuronal response; cross-sectional FDG and volume do not identify initiation or causal mediation." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 8, "pmid": "25342129", "title": "Dysfunctionally phosphorylated type 1 insulin receptor substrate in neural-derived blood exosomes of preclinical Alzheimer's disease.", "citation": "Kapogiannis D, Boxer A, Schwartz JB et al. Dysfunctionally phosphorylated type 1 insulin receptor substrate in neural-derived blood exosomes of preclinical Alzheimer's disease. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2015.", "doi": "10.1096/fj.14-262048", "pmcid": "PMC4314222", "url": "https://pubmed.ncbi.nlm.nih.gov/25342129/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/25342129/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID25342129", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC3" ], "favors_models": [], "evidence_class": "Weak", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Immunocaptured putative neural exosome IRS1 measures differ in AD, diabetes and FTD; 22 future AD cases show differences 1-10 years before diagnosis.", "what_it_does_not_show": "Preclinical clinical timing does not precede amyloid/tau necessarily. Small selected case-control series, classifier validation and disputed L1CAM enrichment constrain neuronal provenance and prediction generalization.", "confounders_present": [ "Preclinical clinical timing does not precede amyloid/tau necessarily. Small selected case-control series, classifier validation and disputed L1CAM enrichment constrain neuronal provenance and prediction generalization." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [ "Early L1CAM/IRS1 immunocapture programme; later assays are not independent validation of its exact classifier." ] }, { "n": 9, "pmid": "33160263", "title": "Neuronal insulin signaling and brain structure in nondemented older adults: the Atherosclerosis Risk in Communities Study.", "citation": "Walker KA, Chawla S, Nogueras-Ortiz C et al. Neuronal insulin signaling and brain structure in nondemented older adults: the Atherosclerosis Risk in Communities Study. Neurobiology of aging. 2021.", "doi": "10.1016/j.neurobiolaging.2020.09.022", "pmcid": "PMC7736127", "url": "https://pubmed.ncbi.nlm.nih.gov/33160263/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33160263/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID33160263", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC3" ], "favors_models": [], "evidence_class": "Weak", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "L1CAM-enriched vesicle insulin-signalling composite associates with less WMH and greater temporal volume in 88 nondemented ARIC-PET participants.", "what_it_does_not_show": "Cross-sectional association, amyloid-dependent attenuation and uncertain neuronal vesicle isolation do not establish causal neuronal signalling or prelesion initiation.", "confounders_present": [ "Cross-sectional association, amyloid-dependent attenuation and uncertain neuronal vesicle isolation do not establish causal neuronal signalling or prelesion initiation." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 10, "pmid": "34092791", "title": "L1CAM is not associated with extracellular vesicles in human cerebrospinal fluid or plasma.", "citation": "Norman M, Ter-Ovanesyan D, Trieu W et al. L1CAM is not associated with extracellular vesicles in human cerebrospinal fluid or plasma. Nature methods. 2021.", "doi": "10.1038/s41592-021-01174-8", "pmcid": "PMC9075416", "url": "https://pubmed.ncbi.nlm.nih.gov/34092791/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/34092791/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID34092791", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "assay validation", "decisive_perturbation": true, "endogenous": false, "direction": "contradicts", "what_it_shows": "Orthogonal biofluid fractionation and single-molecule assays find L1CAM largely outside extracellular vesicles, challenging common neuronal immunocapture assumptions.", "what_it_does_not_show": "This validates an assay limitation rather than absence of all neural EVs or falsity of every IRS1 signal; protocol and antibody-specific follow-up is necessary.", "confounders_present": [ "This validates an assay limitation rather than absence of all neural EVs or falsity of every IRS1 signal; protocol and antibody-specific follow-up is necessary." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 11, "pmid": "38868956", "title": "Single-extracellular vesicle (EV) analyses validate the use of L1 Cell Adhesion Molecule (L1CAM) as a reliable biomarker of neuron-derived EVs.", "citation": "Nogueras-Ortiz CJ, Eren E, Yao P et al. Single-extracellular vesicle (EV) analyses validate the use of L1 Cell Adhesion Molecule (L1CAM) as a reliable biomarker of neuron-derived EVs. Journal of extracellular vesicles. 2024.", "doi": "10.1002/jev2.12459", "pmcid": "PMC11170079", "url": "https://pubmed.ncbi.nlm.nih.gov/38868956/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/38868956/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID38868956", "access_depth": "full_text_partial", "access_note": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:RESULTS:paragraph6, 1:RESULTS:paragraph9, 1:RESULTS:paragraph12, 1:RESULTS:paragraph15, 1:RESULTS:paragraph18. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "assay validation", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "Single-EV methods find L1CAM epitopes co-expressed with neuronal proteins and enrichment relative to L1CAM-negative EVs.", "what_it_does_not_show": "Original Results include detergent, isotype, background, tetraspanin and hepatocyte-marker controls; 5G3 immunocapture enriches a subset co-carrying neuronal markers. Most soluble L1CAM remains outside EVs. This supports specific procedures rather than universal neuronal purity or live-cell insulin response.", "confounders_present": [ "Original Results include detergent, isotype, background, tetraspanin and hepatocyte-marker controls; 5G3 immunocapture enriches a subset co-carrying neuronal markers. Most soluble L1CAM remains outside EVs. This supports specific procedures rather than universal neuronal purity or live-cell insulin response." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 12, "pmid": "40210837", "title": "Most L1CAM Is not Associated with Extracellular Vesicles in Human Biofluids and iPSC-Derived Neurons.", "citation": "Kadam V, Wacker M, Oeckl P et al. Most L1CAM Is not Associated with Extracellular Vesicles in Human Biofluids and iPSC-Derived Neurons. Molecular neurobiology. 2025.", "doi": "10.1007/s12035-025-04909-2", "pmcid": "PMC12289729", "url": "https://pubmed.ncbi.nlm.nih.gov/40210837/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/40210837/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID40210837", "access_depth": "full_text_partial", "access_note": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Materials and Methods:paragraph3, 1:Materials and Methods:paragraph9, 1:Materials and Methods:paragraph13, 2:Results:paragraph2, 2:Results:paragraph3, 2:Results:paragraph7, 2:Results:paragraph9, 2:Results:paragraph10, 2:Results:paragraph12. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "assay validation", "decisive_perturbation": true, "endogenous": false, "direction": "contradicts", "what_it_shows": "Across plasma, CSF and induced-neuron media, generic EVs and neuronal cargo are recovered but L1CAM predominantly remains free and is not enriched by immunocapture.", "what_it_does_not_show": "Original Methods/Results use the same common 5G3 clone, calnexin-negative capture, EV markers, neuronal versus hematopoietic media and free-protein fractions. CSF proteomics is one pooled experiment. Negative enrichment differs from single-EV positive procedures; neither result measures live neuronal insulin causality.", "confounders_present": [ "Original Methods/Results use the same common 5G3 clone, calnexin-negative capture, EV markers, neuronal versus hematopoietic media and free-protein fractions. CSF proteomics is one pooled experiment. Negative enrichment differs from single-EV positive procedures; neither result measures live neuronal insulin causality." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 13, "pmid": "14981233", "title": "Role for neuronal insulin resistance in neurodegenerative diseases.", "citation": "Schubert M, Gautam D, Surjo D et al. Role for neuronal insulin resistance in neurodegenerative diseases. Proceedings of the National Academy of Sciences of the United States of America. 2004.", "doi": "10.1073/pnas.0308724101", "pmcid": "PMC365750", "url": "https://pubmed.ncbi.nlm.nih.gov/14981233/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/14981233/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID14981233", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "genetic mouse", "decisive_perturbation": true, "endogenous": true, "direction": "contradicts", "what_it_shows": "NIRKO loses insulin-mediated signalling and increases tau phosphorylation while showing no neuronal survival, memory or basal brain glucose deficit.", "what_it_does_not_show": "Developmental deletion and compensation may mask adult functions, but marker changes alone are insufficient to generate AD-like functional degeneration in this tested context.", "confounders_present": [ "Developmental deletion and compensation may mask adult functions, but marker changes alone are insufficient to generate AD-like functional degeneration in this tested context." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [ "NIRKO lineage related to PMID11000114; different phenotype analyses are not independent genetic systems." ] }, { "n": 14, "pmid": "12904469", "title": "Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation.", "citation": "Schubert M, Brazil DP, Burks DJ et al. Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2003.", "doi": "10.1523/JNEUROSCI.23-18-07084.2003", "pmcid": "PMC6740672", "url": "https://pubmed.ncbi.nlm.nih.gov/12904469/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/12904469/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID12904469", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "genetic mouse", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Global IRS2 loss reduces developmental neuronal proliferation and older mice accumulate phosphorylated tau pathology.", "what_it_does_not_show": "Major developmental growth and peripheral diabetes effects prevent isolation of an adult neuronal initiating mechanism or specificity to sporadic AD.", "confounders_present": [ "Major developmental growth and peripheral diabetes effects prevent isolation of an adult neuronal initiating mechanism or specificity to sporadic AD." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 15, "pmid": "11000114", "title": "Role of brain insulin receptor in control of body weight and reproduction.", "citation": "Brüning JC, Gautam D, Burks DJ et al. Role of brain insulin receptor in control of body weight and reproduction. Science (New York, N.Y.). 2000.", "doi": "10.1126/science.289.5487.2122", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/11000114/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/11000114/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID11000114", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "genetic mouse", "decisive_perturbation": true, "endogenous": true, "direction": "contradicts", "what_it_shows": "Neural insulin-receptor deletion alters feeding, obesity and reproductive control without altered brain development or neuronal survival.", "what_it_does_not_show": "Systemic consequences and developmental timing matter; metabolic regulation by brain IR is not sufficient proof of AD initiation.", "confounders_present": [ "Systemic consequences and developmental timing matter; metabolic regulation by brain IR is not sufficient proof of AD initiation." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 16, "pmid": "26290229", "title": "Blocking IGF Signaling in Adult Neurons Alleviates Alzheimer's Disease Pathology through Amyloid-β Clearance.", "citation": "Gontier G, George C, Chaker Z et al. Blocking IGF Signaling in Adult Neurons Alleviates Alzheimer's Disease Pathology through Amyloid-β Clearance. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2015.", "doi": "10.1523/JNEUROSCI.0343-15.2015", "pmcid": "PMC6605240", "url": "https://pubmed.ncbi.nlm.nih.gov/26290229/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/26290229/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "Adult-neuronal-IGF1R-programme", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "adult conditional transgenic mouse", "decisive_perturbation": true, "endogenous": false, "direction": "contradicts", "what_it_shows": "Adult neuron-specific IGF1R deletion in APP/PS1 mice improves spatial memory and reduces amyloid/inflammation, with neuronal structural changes and higher plasma amyloid.", "what_it_does_not_show": "The direction opposes simple restoration of deficient IGF signalling. An adult genetic intervention is credited, but an APP/PS1 disease substrate and cell-size/proteostasis effects do not establish sporadic human primacy.", "confounders_present": [ "The direction opposes simple restoration of deficient IGF signalling. An adult genetic intervention is credited, but an APP/PS1 disease substrate and cell-size/proteostasis effects do not establish sporadic human primacy." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 17, "pmid": "19487308", "title": "Neuronal IGF-1 resistance reduces Abeta accumulation and protects against premature death in a model of Alzheimer's disease.", "citation": "Freude S, Hettich MM, Schumann C et al. Neuronal IGF-1 resistance reduces Abeta accumulation and protects against premature death in a model of Alzheimer's disease. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2009.", "doi": "10.1096/fj.09-132043", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/19487308/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/19487308/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID19487308", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "genetic transgenic mouse", "decisive_perturbation": true, "endogenous": false, "direction": "contradicts", "what_it_shows": "IRS2 or neuronal IGF1R loss reduces amyloid and prevents premature Tg2576 death; neuronal IR loss does not alter lethality.", "what_it_does_not_show": "Insulin and IGF branches differ. Developmental manipulation, sex differences and transgenic premature mortality constrain interpretation as natural aging or sporadic AD.", "confounders_present": [ "Insulin and IGF branches differ. Developmental manipulation, sex differences and transgenic premature mortality constrain interpretation as natural aging or sporadic AD." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [ "Tg2576/IRS2 lineage shares developmental/systemic constraints with other deletion studies." ] }, { "n": 18, "pmid": "20005808", "title": "Reduced IGF-1 signaling delays age-associated proteotoxicity in mice.", "citation": "Cohen E, Paulsson JF, Blinder P et al. Reduced IGF-1 signaling delays age-associated proteotoxicity in mice. Cell. 2009.", "doi": "10.1016/j.cell.2009.11.014", "pmcid": "PMC3017511", "url": "https://pubmed.ncbi.nlm.nih.gov/20005808/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/20005808/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID20005808", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "genetic transgenic mouse", "decisive_perturbation": true, "endogenous": false, "direction": "contradicts", "what_it_shows": "Reduced IGF signalling protects AD-model mice against behavioural deficits, inflammation and neuronal loss while promoting dense amyloid aggregates.", "what_it_does_not_show": "Protection from reduced signalling challenges a uniformly deficient-signalling model; developmental, aggregation and transgenic-context effects remain.", "confounders_present": [ "Protection from reduced signalling challenges a uniformly deficient-signalling model; developmental, aggregation and transgenic-context effects remain." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 19, "pmid": "28652303", "title": "Tau deletion promotes brain insulin resistance.", "citation": "Marciniak E, Leboucher A, Caron E et al. Tau deletion promotes brain insulin resistance. The Journal of experimental medicine. 2017.", "doi": "10.1084/jem.20161731", "pmcid": "PMC5551570", "url": "https://pubmed.ncbi.nlm.nih.gov/28652303/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/28652303/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID28652303", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "genetic mouse and human genetics", "decisive_perturbation": true, "endogenous": true, "direction": "contradicts", "what_it_shows": "Tau deletion impairs hippocampal insulin response through IRS1/PTEN and changes hypothalamic insulin effects; human tau haplotypes associate with glycemic traits.", "what_it_does_not_show": "Provides a tau-to-insulin direction in models, not proof of the sole human ordering; lifelong deletion and peripheral glycemic traits do not reproduce pathological tau loss selectively.", "confounders_present": [ "Provides a tau-to-insulin direction in models, not proof of the sole human ordering; lifelong deletion and peripheral glycemic traits do not reproduce pathological tau loss selectively." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 20, "pmid": "22476196", "title": "An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers.", "citation": "Bomfim TR, Forny-Germano L, Sathler LB et al. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers. The Journal of clinical investigation. 2012.", "doi": "10.1172/JCI57256", "pmcid": "PMC3314445", "url": "https://pubmed.ncbi.nlm.nih.gov/22476196/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/22476196/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID22476196", "access_depth": "full_text_partial", "access_note": "Complete primary abstract and linked-status metadata examined. Selected body sections: Results:Figure8 and exendin4 rescue; Methods:primate infusion, APP/PS1 animals and behavioural tests. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "cell culture and transgenic/challenge animal", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "Amyloid oligomers activate JNK/TNF, inhibit IRS1 signalling in neurons and primate challenge, while exendin4 restores neuronal transport and improves transgenic-mouse cognition.", "what_it_does_not_show": "Original Methods use male APP/PS1 mice and imposed primate oligomers; behavioural treatment starts at nine months. Comparable slight weight loss limits a simple caloric explanation, but GLP1 pleiotropy and no neuronal-IR-specific epistasis remain. Amyloid can induce resistance; rescue does not establish primary sporadic initiation.", "confounders_present": [ "Original Methods use male APP/PS1 mice and imposed primate oligomers; behavioural treatment starts at nine months. Comparable slight weight loss limits a simple caloric explanation, but GLP1 pleiotropy and no neuronal-IR-specific epistasis remain. Amyloid can induce resistance; rescue does not establish primary sporadic initiation." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 21, "pmid": "24315369", "title": "TNF-α mediates PKR-dependent memory impairment and brain IRS-1 inhibition induced by Alzheimer's β-amyloid oligomers in mice and monkeys.", "citation": "Lourenco MV, Clarke JR, Frozza RL et al. TNF-α mediates PKR-dependent memory impairment and brain IRS-1 inhibition induced by Alzheimer's β-amyloid oligomers in mice and monkeys. Cell metabolism. 2013.", "doi": "10.1016/j.cmet.2013.11.002", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/24315369/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/24315369/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID24315369", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "genetic challenge mouse and primate", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "TNFR1/PKR disruption blocks oligomer-induced translation-signalling changes and memory impairment; insulin support rescues pathway abnormalities.", "what_it_does_not_show": "Challenge genetics establish an amyloid-to-inflammatory/IRS1 injury route, not endogenous sporadic neuronal insulin failure as the first lesion.", "confounders_present": [ "Challenge genetics establish an amyloid-to-inflammatory/IRS1 injury route, not endogenous sporadic neuronal insulin failure as the first lesion." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 22, "pmid": "19188609", "title": "Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers.", "citation": "De Felice FG, Vieira MN, Bomfim TR et al. Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proceedings of the National Academy of Sciences of the United States of America. 2009.", "doi": "10.1073/pnas.0809158106", "pmcid": "PMC2634809", "url": "https://pubmed.ncbi.nlm.nih.gov/19188609/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/19188609/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "ErratumIn: PMID not supplied" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID19188609", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Weak", "system": "neuronal culture", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "Insulin prevents oligomer-induced surface IR loss, oxidative stress and spine deterioration; kinase inhibition abolishes protection and rosiglitazone potentiates it.", "what_it_does_not_show": "Culture rescue does not establish organismal trajectory change or natural initiation. A linked unidentified erratum remains unresolved.", "confounders_present": [ "Culture rescue does not establish organismal trajectory change or natural initiation. A linked unidentified erratum remains unresolved." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 23, "pmid": "25543463", "title": "Modulation of insulin signaling rescues BDNF transport defects independent of tau in amyloid-β oligomer-treated hippocampal neurons.", "citation": "Takach O, Gill TB, Silverman MA et al. Modulation of insulin signaling rescues BDNF transport defects independent of tau in amyloid-β oligomer-treated hippocampal neurons. Neurobiology of aging. 2015.", "doi": "10.1016/j.neurobiolaging.2014.11.018", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/25543463/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/25543463/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID25543463", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Weak", "system": "neuronal culture", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "Active AKT, GSK3 inhibition and exendin4 prevent or reverse oligomer-induced BDNF transport deficits in wild-type and tau-null neurons.", "what_it_does_not_show": "A transport rescue after imposed amyloid is narrower than survival or clinical benefit and is compatible with a reinforcing feedback pathway.", "confounders_present": [ "A transport rescue after imposed amyloid is narrower than survival or clinical benefit and is compatible with a reinforcing feedback pathway." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 24, "pmid": "28302722", "title": "Amyloid-β oligomers transiently inhibit AMP-activated kinase and cause metabolic defects in hippocampal neurons.", "citation": "Seixas da Silva GS, Melo HM, Lourenco MV et al. Amyloid-β oligomers transiently inhibit AMP-activated kinase and cause metabolic defects in hippocampal neurons. The Journal of biological chemistry. 2017.", "doi": "10.1074/jbc.M116.753525", "pmcid": "PMC5418041", "url": "https://pubmed.ncbi.nlm.nih.gov/28302722/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/28302722/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID28302722", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Weak", "system": "neuronal culture and human ex-vivo", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "Oligomers transiently inhibit AMPK/ATP and remove dendritic glucose transporters; NMDA-related intervention and insulin protect these measures.", "what_it_does_not_show": "Acute metabolic responses after imposed amyloid are not proof of primary neuronal insulin resistance or sustained organismal disease modification.", "confounders_present": [ "Acute metabolic responses after imposed amyloid are not proof of primary neuronal insulin resistance or sustained organismal disease modification." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 25, "pmid": "30652125", "title": "Insulin signaling in Drosophila melanogaster mediates Aβ toxicity.", "citation": "Huang Y, Wan Z, Wang Z et al. Insulin signaling in Drosophila melanogaster mediates Aβ toxicity. Communications biology. 2019.", "doi": "10.1038/s42003-018-0253-x", "pmcid": "PMC6325060", "url": "https://pubmed.ncbi.nlm.nih.gov/30652125/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/30652125/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID30652125", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "genetic transgenic fly", "decisive_perturbation": true, "endogenous": false, "direction": "contradicts", "what_it_shows": "Reducing fly insulin signalling suppresses expressed-Aβ toxicity; Aβ elevates brain insulin signalling while peripheral signalling falls.", "what_it_does_not_show": "A different species adds direction discrimination but is an imposed peptide system; IDE competition and branch/tissue effects oppose a simple low-signalling master mechanism.", "confounders_present": [ "A different species adds direction discrimination but is an imposed peptide system; IDE competition and branch/tissue effects oppose a simple low-signalling master mechanism." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 26, "pmid": "22661254", "title": "Insulin receptor β-subunit haploinsufficiency impairs hippocampal late-phase LTP and recognition memory.", "citation": "Nisticò R, Cavallucci V, Piccinin S et al. Insulin receptor β-subunit haploinsufficiency impairs hippocampal late-phase LTP and recognition memory. Neuromolecular medicine. 2012.", "doi": "10.1007/s12017-012-8184-z", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/22661254/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/22661254/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID22661254", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2" ], "favors_models": [], "evidence_class": "Moderate", "system": "genetic mouse", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "IR beta-subunit haploinsufficiency impairs late LTP and recognition memory.", "what_it_does_not_show": "A lifelong global dosage change demonstrates a memory contribution in this background, not adult neuron-specific AD initiation or neurodegenerative trajectory.", "confounders_present": [ "A lifelong global dosage change demonstrates a memory contribution in this background, not adult neuron-specific AD initiation or neurodegenerative trajectory." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 27, "pmid": "31915254", "title": "Neuronal Protein Tyrosine Phosphatase 1B Hastens Amyloid β-Associated Alzheimer's Disease in Mice.", "citation": "Ricke KM, Cruz SA, Qin Z et al. Neuronal Protein Tyrosine Phosphatase 1B Hastens Amyloid β-Associated Alzheimer's Disease in Mice. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2020.", "doi": "10.1523/JNEUROSCI.2120-19.2019", "pmcid": "PMC7044730", "url": "https://pubmed.ncbi.nlm.nih.gov/31915254/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/31915254/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID31915254", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "genetic and pharmacologic transgenic mouse", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "Neuronal PTP1B ablation and systemic trodusquemine prevent neuron loss and spatial memory deficits in hAPP-J20 mice; neuronal ablation preserves benefit without reducing inflammation.", "what_it_does_not_show": "An endogenous signalling regulator is tested within an amyloid transgenic substrate, but PTP1B affects multiple receptors; restoration of insulin signalling specifically is not isolated by the abstract.", "confounders_present": [ "An endogenous signalling regulator is tested within an amyloid transgenic substrate, but PTP1B affects multiple receptors; restoration of insulin signalling specifically is not isolated by the abstract." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 28, "pmid": "28595357", "title": "The Alzheimer's disease transcriptome mimics the neuroprotective signature of IGF-1 receptor-deficient neurons.", "citation": "George C, Gontier G, Lacube P et al. The Alzheimer's disease transcriptome mimics the neuroprotective signature of IGF-1 receptor-deficient neurons. Brain : a journal of neurology. 2017.", "doi": "10.1093/brain/awx132", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/28595357/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/28595357/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "Adult-neuronal-IGF1R-programme", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "adult genetic challenge/transgenic mouse", "decisive_perturbation": true, "endogenous": false, "direction": "contradicts", "what_it_shows": "Adult neuronal IGF1R suppression protects against oligomer-induced memory and inflammatory injury; related APP/PS1 transcriptional signatures converge.", "what_it_does_not_show": "Shares the adult IGF-deletion programme with PMID26290229. Transcriptomic similarity is a lead, not independent causal proof; loss of the IGF branch again protects rather than harms.", "confounders_present": [ "Shares the adult IGF-deletion programme with PMID26290229. Transcriptomic similarity is a lead, not independent causal proof; loss of the IGF branch again protects rather than harms." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 29, "pmid": "25617315", "title": "Alzheimer-associated Aβ oligomers impact the central nervous system to induce peripheral metabolic deregulation.", "citation": "Clarke JR, Lyra E Silva NM, Figueiredo CP et al. Alzheimer-associated Aβ oligomers impact the central nervous system to induce peripheral metabolic deregulation. EMBO molecular medicine. 2015.", "doi": "10.15252/emmm.201404183", "pmcid": "PMC4328648", "url": "https://pubmed.ncbi.nlm.nih.gov/25617315/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/25617315/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID25617315", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "genetic and pharmacologic challenge animal", "decisive_perturbation": true, "endogenous": false, "direction": "contradicts", "what_it_shows": "Central, but not systemic, oligomer infusion induces peripheral glucose intolerance; TNFR1 loss and central inflammatory/ER-stress inhibition prevent it.", "what_it_does_not_show": "Demonstrates brain injury can drive peripheral metabolic change. Imposed exposure and transgenics do not establish native human direction or exclude reciprocal metabolic risk.", "confounders_present": [ "Demonstrates brain injury can drive peripheral metabolic change. Imposed exposure and transgenics do not establish native human direction or exclude reciprocal metabolic risk." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 30, "pmid": "29664737", "title": "Insulin regulates astrocyte gliotransmission and modulates behavior.", "citation": "Cai W, Xue C, Sakaguchi M et al. Insulin regulates astrocyte gliotransmission and modulates behavior. The Journal of clinical investigation. 2018.", "doi": "10.1172/JCI99366", "pmcid": "PMC6025980", "url": "https://pubmed.ncbi.nlm.nih.gov/29664737/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/29664737/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID29664737", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2" ], "favors_models": [], "evidence_class": "Moderate", "system": "conditional genetic mouse", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Astrocyte IR deletion alters ATP exocytosis and dopamine-related behaviour; central ATP analog rescues depressive-like behaviour.", "what_it_does_not_show": "A cell-type-specific glial route is functional but is neither neuronal insulin resistance nor AD initiation, and the behavioural endpoint is not AD cognitive trajectory.", "confounders_present": [ "A cell-type-specific glial route is functional but is neither neuronal insulin resistance nor AD initiation, and the behavioural endpoint is not AD cognitive trajectory." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 31, "pmid": "29398615", "title": "Insulin-like growth factor receptor signaling regulates working memory, mitochondrial metabolism, and amyloid-β uptake in astrocytes.", "citation": "Logan S, Pharaoh GA, Marlin MC et al. Insulin-like growth factor receptor signaling regulates working memory, mitochondrial metabolism, and amyloid-β uptake in astrocytes. Molecular metabolism. 2018.", "doi": "10.1016/j.molmet.2018.01.013", "pmcid": "PMC5870102", "url": "https://pubmed.ncbi.nlm.nih.gov/29398615/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/29398615/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID29398615", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2" ], "favors_models": [], "evidence_class": "Moderate", "system": "adult conditional genetic mouse", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Inducible astrocyte IGFR loss impairs working memory, mitochondrial function and glucose/amyloid uptake.", "what_it_does_not_show": "Astrocytic support differs from adult neuronal IGFR loss; single-context functional benefit and cultured mitochondrial changes do not establish a uniform neuronal mechanism.", "confounders_present": [ "Astrocytic support differs from adult neuronal IGFR loss; single-context functional benefit and cultured mitochondrial changes do not establish a uniform neuronal mechanism." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 32, "pmid": "40388612", "title": "Loss of insulin signaling in microglia impairs cellular uptake of Aβ and neuroinflammatory response exacerbating AD-like neuropathology.", "citation": "Chen W, Liu X, Muñoz VR et al. Loss of insulin signaling in microglia impairs cellular uptake of Aβ and neuroinflammatory response exacerbating AD-like neuropathology. Proceedings of the National Academy of Sciences of the United States of America. 2025.", "doi": "10.1073/pnas.2501527122", "pmcid": "PMC12130885", "url": "https://pubmed.ncbi.nlm.nih.gov/40388612/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/40388612/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "UpdateOf: PMID39229221" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID40388612", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "adult conditional genetic transgenic mouse", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "Inducible microglial IR loss impairs amyloid uptake and increases plaque/inflammation in 5xFAD, with mood/social changes.", "what_it_does_not_show": "Microglial rather than neuronal perturbation, an imposed familial substrate and no demonstrated AD cognitive rescue constrain the registered neuronal claim. Updated preprint is not counted again.", "confounders_present": [ "Microglial rather than neuronal perturbation, an imposed familial substrate and no demonstrated AD cognitive rescue constrain the registered neuronal claim. Updated preprint is not counted again." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 33, "pmid": "33291072", "title": "High-fat diet induced discrepant peripheral and central nervous systems insulin resistance in APPswe/PS1dE9 and wild-type C57BL/6J mice.", "citation": "Guo Y, Ma X, Li P et al. High-fat diet induced discrepant peripheral and central nervous systems insulin resistance in APPswe/PS1dE9 and wild-type C57BL/6J mice. Aging. 2020.", "doi": "10.18632/aging.202262", "pmcid": "PMC7835010", "url": "https://pubmed.ncbi.nlm.nih.gov/33291072/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33291072/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID33291072", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "diet intervention transgenic mouse", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "Prolonged high-fat diet worsens cognition and soluble amyloid in APP/PS1 mice while central and peripheral transporter responses differ.", "what_it_does_not_show": "Diet begins at one month and changes lipids/inflammation/intake; broad developmental and systemic exposure cannot isolate adult neuronal insulin resistance.", "confounders_present": [ "Diet begins at one month and changes lipids/inflammation/intake; broad developmental and systemic exposure cannot isolate adult neuronal insulin resistance." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 34, "pmid": "20110613", "title": "Insulin-resistant brain state after intracerebroventricular streptozotocin injection exacerbates Alzheimer-like changes in Tg2576 AbetaPP-overexpressing mice.", "citation": "Plaschke K, Kopitz J, Siegelin M et al. Insulin-resistant brain state after intracerebroventricular streptozotocin injection exacerbates Alzheimer-like changes in Tg2576 AbetaPP-overexpressing mice. Journal of Alzheimer's disease : JAD. 2010.", "doi": "10.3233/JAD-2010-1270", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/20110613/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/20110613/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID20110613", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "toxic challenge transgenic mouse", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "Intracerebroventricular STZ worsens Tg2576 spatial cognition, mortality and amyloid/tau measures.", "what_it_does_not_show": "STZ is a toxic imposed trigger with effects beyond insulin signalling. Combining it with APP overexpression is not selective sufficiency for sporadic AD.", "confounders_present": [ "STZ is a toxic imposed trigger with effects beyond insulin signalling. Combining it with APP overexpression is not selective sufficiency for sporadic AD." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 35, "pmid": "27173425", "title": "Experimentally induced diabetes worsens neuropathology, but not learning and memory, in middle aged 3xTg mice.", "citation": "Hayashi-Park E, Ozment BN, Griffith CM et al. Experimentally induced diabetes worsens neuropathology, but not learning and memory, in middle aged 3xTg mice. Behavioural brain research. 2017.", "doi": "10.1016/j.bbr.2016.05.020", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/27173425/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/27173425/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID27173425", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "toxic challenge transgenic mouse", "decisive_perturbation": true, "endogenous": false, "direction": "contradicts", "what_it_shows": "Induced diabetes increases subicular amyloid plaques in middle-aged 3xTg mice but does not worsen learning/memory or AT8 burden.", "what_it_does_not_show": "A functional negative comparator prevents biomarker-only changes earning trajectory credit; dose, timing and model baseline bound the null result.", "confounders_present": [ "A functional negative comparator prevents biomarker-only changes earning trajectory credit; dose, timing and model baseline bound the null result." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 36, "pmid": "34420950", "title": "Alzheimer's Disease-Related Neuropathology Among Patients with Medication Treated Type 2 Diabetes in a Community-Based Autopsy Cohort.", "citation": "Barthold D, Gibbons LE, Marcum ZA et al. Alzheimer's Disease-Related Neuropathology Among Patients with Medication Treated Type 2 Diabetes in a Community-Based Autopsy Cohort. Journal of Alzheimer's disease : JAD. 2021.", "doi": "10.3233/JAD-210059", "pmcid": "PMC8846930", "url": "https://pubmed.ncbi.nlm.nih.gov/34420950/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/34420950/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID34420950", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC4" ], "favors_models": [], "evidence_class": "Weak", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "mixed", "what_it_shows": "In 118 medication-treated ACT autopsies, conventional AD neuropathology is not associated with drug class; some adjusted quantitative amyloid measures are lower.", "what_it_does_not_show": "Small descriptive analysis and indication/severity confounding cannot establish therapeutic neuronal insulin mediation or clinical disease modification.", "confounders_present": [ "Small descriptive analysis and indication/severity confounding cannot establish therapeutic neuronal insulin mediation or clinical disease modification." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 37, "pmid": "33858515", "title": "Brain insulin signaling and cerebrovascular disease in human postmortem brain.", "citation": "Arvanitakis Z, Capuano AW, Wang HY et al. Brain insulin signaling and cerebrovascular disease in human postmortem brain. Acta neuropathologica communications. 2021.", "doi": "10.1186/s40478-021-01176-9", "pmcid": "PMC8048276", "url": "https://pubmed.ncbi.nlm.nih.gov/33858515/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33858515/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "ROS-150-matched-brains", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "human ex-vivo and observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "In the same 150 ROS brains, stimulated AKT and cytoplasmic IRS1 measures associate with infarcts, with a separate amyloid-angiopathy association.", "what_it_does_not_show": "Shared cohort adds vascular specificity rather than independent replication; infarction can cause cognition/AD-like symptoms without proving neuronal insulin primacy.", "confounders_present": [ "Shared cohort adds vascular specificity rather than independent replication; infarction can cause cognition/AD-like symptoms without proving neuronal insulin primacy." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 38, "pmid": "10599761", "title": "Diabetes mellitus and the risk of dementia: The Rotterdam Study.", "citation": "Ott A, Stolk RP, van Harskamp F et al. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology. 1999.", "doi": "10.1212/wnl.53.9.1937", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/10599761/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/10599761/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID10599761", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3" ], "favors_models": [], "evidence_class": "Weak", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Prospective Rotterdam data link diabetes to incident clinically diagnosed dementia and AD over mean 2.1 years.", "what_it_does_not_show": "Peripheral diabetes, clinical diagnosis and short prediagnosis follow-up do not distinguish vascular contribution, preclinical reverse causation or neuronal initiating resistance; insulin treatment marks severity.", "confounders_present": [ "Peripheral diabetes, clinical diagnosis and short prediagnosis follow-up do not distinguish vascular contribution, preclinical reverse causation or neuronal initiating resistance; insulin treatment marks severity." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 39, "pmid": "24706014", "title": "Insulin-like growth factor-1 and risk of Alzheimer dementia and brain atrophy.", "citation": "Westwood AJ, Beiser A, Decarli C et al. Insulin-like growth factor-1 and risk of Alzheimer dementia and brain atrophy. Neurology. 2014.", "doi": "10.1212/WNL.0000000000000382", "pmcid": "PMC4013812", "url": "https://pubmed.ncbi.nlm.nih.gov/24706014/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/24706014/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID24706014", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3" ], "favors_models": [], "evidence_class": "Weak", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Lower serum IGF1 predicts higher AD dementia incidence in Framingham and higher IGF1 associates with greater brain volume.", "what_it_does_not_show": "Serum hormone is not neuronal receptor responsiveness; cohort confounding and clinically dementia-free enrollment do not establish preamyloid initiation.", "confounders_present": [ "Serum hormone is not neuronal receptor responsiveness; cohort confounding and clinically dementia-free enrollment do not establish preamyloid initiation." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 40, "pmid": "39479764", "title": "Causal association between insulin sensitivity index and Alzheimer's disease.", "citation": "Xu F, Wu S, Gao S et al. Causal association between insulin sensitivity index and Alzheimer's disease. Journal of neurochemistry. 2025.", "doi": "10.1111/jnc.16254", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/39479764/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/39479764/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID39479764", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "human genetic instrument", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "Genetically higher peripheral insulin sensitivity associates with lower AD risk in two outcome datasets, with attenuation after adjusting for T2D.", "what_it_does_not_show": "MR is credited as an upper-ladder equivalent on its exposure, but peripheral sensitivity is not a selective neuronal signalling instrument and multivariable attenuation does not by itself prove mediation.", "confounders_present": [ "MR is credited as an upper-ladder equivalent on its exposure, but peripheral sensitivity is not a selective neuronal signalling instrument and multivariable attenuation does not by itself prove mediation." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [ "IGAP/FinnGen outcomes; instruments concern peripheral postprandial sensitivity." ] }, { "n": 41, "pmid": "39350373", "title": "Evaluating the Causal Effect of Type 2 Diabetes on Alzheimer's Disease Using Large-Scale Genetic Data.", "citation": "Liu D, Baranova A, Zhang F et al. Evaluating the Causal Effect of Type 2 Diabetes on Alzheimer's Disease Using Large-Scale Genetic Data. The journal of prevention of Alzheimer's disease. 2024.", "doi": "10.14283/jpad.2024.148", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/39350373/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/39350373/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID39350373", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "human genetic instrument", "decisive_perturbation": true, "endogenous": false, "direction": "null", "what_it_shows": "Large T2D genetic instruments do not show an AD effect in the primary or FinnGen analysis.", "what_it_does_not_show": "Null peripheral-liability estimates do not refute neuronal insulin resistance; largely overlapping FinnGen exposure/outcome samples and disease ascertainment matter.", "confounders_present": [ "Null peripheral-liability estimates do not refute neuronal insulin resistance; largely overlapping FinnGen exposure/outcome samples and disease ascertainment matter." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [ "Large AD GWAS and FinnGen may overlap other MR programmes; FinnGen exposure/outcome samples largely overlap." ] }, { "n": 42, "pmid": "26650880", "title": "Diabetic Phenotypes and Late-Life Dementia Risk: A Mechanism-specific Mendelian Randomization Study.", "citation": "Walter S, Marden JR, Kubzansky LD et al. Diabetic Phenotypes and Late-Life Dementia Risk: A Mechanism-specific Mendelian Randomization Study. Alzheimer disease and associated disorders. 2016.", "doi": "10.1097/WAD.0000000000000128", "pmcid": "PMC4879683", "url": "https://pubmed.ncbi.nlm.nih.gov/26650880/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/26650880/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID26650880", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "human genetic instrument", "decisive_perturbation": true, "endogenous": false, "direction": "mixed", "what_it_shows": "Overall T2D polygenic liability is null for AD, while a mechanism-specific insulin-sensitivity score predicts AD risk in IGAP.", "what_it_does_not_show": "The corresponding HRS cognition association is nonsignificant. Instrument subclass, pleiotropy and shared GWAS require caution, and peripheral sensitivity is not neuron-specific primacy.", "confounders_present": [ "The corresponding HRS cognition association is nonsignificant. Instrument subclass, pleiotropy and shared GWAS require caution, and peripheral sensitivity is not neuron-specific primacy." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [ "IGAP outcome archive shared by other genetic analyses." ] }, { "n": 43, "pmid": "37730113", "title": "Semaglutide ameliorates cognition and glucose metabolism dysfunction in the 3xTg mouse model of Alzheimer's disease via the GLP-1R/SIRT1/GLUT4 pathway.", "citation": "Wang ZJ, Li XR, Chai SF et al. Semaglutide ameliorates cognition and glucose metabolism dysfunction in the 3xTg mouse model of Alzheimer's disease via the GLP-1R/SIRT1/GLUT4 pathway. Neuropharmacology. 2023.", "doi": "10.1016/j.neuropharm.2023.109716", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/37730113/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/37730113/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID37730113", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "pharmacologic transgenic mouse and cell culture", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "Semaglutide improves short-term cognition and glucose/pathology measures in 3xTg mice; SIRT1 inhibition blocks cultured metabolic effects.", "what_it_does_not_show": "Single-background, short-horizon functional benefit and cell-level epistasis do not establish human disease modification or that insulin failure was upstream of transgenic amyloid/tau.", "confounders_present": [ "Single-background, short-horizon functional benefit and cell-level epistasis do not establish human disease modification or that insulin failure was upstream of transgenic amyloid/tau." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 44, "pmid": "24918340", "title": "Intranasal insulin restores insulin signaling, increases synaptic proteins, and reduces Aβ level and microglia activation in the brains of 3xTg-AD mice.", "citation": "Chen Y, Zhao Y, Dai CL et al. Intranasal insulin restores insulin signaling, increases synaptic proteins, and reduces Aβ level and microglia activation in the brains of 3xTg-AD mice. Experimental neurology. 2014.", "doi": "10.1016/j.expneurol.2014.06.004", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/24918340/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/24918340/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID24918340", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC4" ], "favors_models": [], "evidence_class": "Weak", "system": "pharmacologic transgenic mouse", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "Seven-day intranasal insulin in 3xTg mice restores signalling/synaptic proteins and lowers Aβ40 and microglial activation.", "what_it_does_not_show": "No functional benefit is measured here, and tau phosphorylation, glucose transporters and O-GlcNAcylation are unchanged; biomarker effects do not cross the trajectory boundary.", "confounders_present": [ "No functional benefit is measured here, and tau phosphorylation, glucose transporters and O-GlcNAcylation are unchanged; biomarker effects do not cross the trajectory boundary." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 45, "pmid": "15288712", "title": "Intranasal insulin improves memory in humans.", "citation": "Benedict C, Hallschmid M, Hatke A et al. Intranasal insulin improves memory in humans. Psychoneuroendocrinology. 2004.", "doi": "10.1016/j.psyneuen.2004.04.003", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/15288712/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/15288712/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID15288712", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "In 38 healthy participants, eight-week intranasal insulin improves delayed recall without plasma insulin/glucose change.", "what_it_does_not_show": "Normal memory modulation is a credible central-function effect but does not demonstrate AD disease modification or receptor-specific neuronal engagement.", "confounders_present": [ "Normal memory modulation is a credible central-function effect but does not demonstrate AD disease modification or receptor-specific neuronal engagement." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 46, "pmid": "27553192", "title": "An assessment of the central disposition of intranasally administered insulin lispro in the cerebrospinal fluid of healthy volunteers and beagle dogs.", "citation": "Lowe S, Sher E, Wishart G et al. An assessment of the central disposition of intranasally administered insulin lispro in the cerebrospinal fluid of healthy volunteers and beagle dogs. Drug delivery and translational research. 2017.", "doi": "10.1007/s13346-016-0325-8", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/27553192/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/27553192/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID27553192", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "human and animal pharmacokinetic", "decisive_perturbation": true, "endogenous": false, "direction": "contradicts", "what_it_shows": "With the tested Aero Pump lispro regimen, human CSF drug is below quantification despite detection in beagle CSF.", "what_it_does_not_show": "Direct delivery limitation is regimen/species-specific; CSF absence does not universally exclude local brain delivery, but animal exposure cannot validate human delivery.", "confounders_present": [ "Direct delivery limitation is regimen/species-specific; CSF absence does not universally exclude local brain delivery, but animal exposure cannot validate human delivery." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 47, "pmid": "40703476", "title": "First-in-human positron emission tomography study of intranasal insulin in aging and MCI.", "citation": "Sai KKS, Erichsen JM, Gollapelli KK et al. First-in-human positron emission tomography study of intranasal insulin in aging and MCI. Alzheimer's & dementia (New York, N. Y.). 2025.", "doi": "10.1002/trc2.70123", "pmcid": "PMC12284729", "url": "https://pubmed.ncbi.nlm.nih.gov/40703476/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/40703476/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID40703476", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "human pharmacokinetic imaging", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "Intranasal radiolabelled insulin with an Aptar device reaches multiple brain regions in 16 older CN/MCI participants.", "what_it_does_not_show": "Radiotracer distribution validates this device/exposure route, not therapeutic receptor phosphorylation, sustained bioactive concentration or clinical efficacy in other devices.", "confounders_present": [ "Radiotracer distribution validates this device/exposure route, not therapeutic receptor phosphorylation, sustained bioactive concentration or clinical efficacy in other devices." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 48, "pmid": "17942819", "title": "Intranasal insulin improves cognition and modulates beta-amyloid in early AD.", "citation": "Reger MA, Watson GS, Green PS et al. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology. 2008.", "doi": "10.1212/01.WNL.0000265401.62434.36", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/17942819/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/17942819/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "ErratumIn: PMID not supplied" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID17942819", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Twenty-one-day randomized insulin pilot improves delayed recall, attention and caregiver function in 25 early AD/MCI participants without changed fasting insulin/glucose.", "what_it_does_not_show": "Small short-term clinical changes can be symptomatic; multiple outcomes, diagnostic heterogeneity and an unresolved linked erratum limit trajectory inference.", "confounders_present": [ "Small short-term clinical changes can be symptomatic; multiple outcomes, diagnostic heterogeneity and an unresolved linked erratum limit trajectory inference." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 49, "pmid": "21911655", "title": "Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial.", "citation": "Craft S, Baker LD, Montine TJ et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Archives of neurology. 2012.", "doi": "10.1001/archneurol.2011.233", "pmcid": "PMC3260944", "url": "https://pubmed.ncbi.nlm.nih.gov/21911655/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/21911655/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID21911655", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Four-month 104-person pilot finds improved delayed memory at 20 IU and preserved caregiver function at both doses, with exploratory FDG and CSF correlations.", "what_it_does_not_show": "Small endpoint subsets, subgroup effects and no group CSF biomarker shift do not establish durable disease modification or selective neuronal insulin correction.", "confounders_present": [ "Small endpoint subsets, subgroup effects and no group CSF biomarker shift do not establish durable disease modification or selective neuronal insulin correction." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 50, "pmid": "25374101", "title": "Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer's disease dementia.", "citation": "Claxton A, Baker LD, Hanson A et al. Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer's disease dementia. Journal of Alzheimer's disease : JAD. 2015.", "doi": "10.3233/JAD-141791", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/25374101/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/25374101/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "ErratumIn: PMID25869922" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID25374101", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "mixed", "what_it_shows": "In a 60-person 21-day detemir trial, high-dose memory effects differ by APOE, with improvement in carriers and worsening in noncarriers; daily function is null.", "what_it_does_not_show": "Short-term, genotype-dependent effects require replication; baseline peripheral resistance is not brain target engagement. Linked erratum PMID25869922 is not a primary study.", "confounders_present": [ "Short-term, genotype-dependent effects require replication; baseline peripheral resistance is not brain target engagement. Linked erratum PMID25869922 is not a primary study." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 51, "pmid": "28372335", "title": "Effects of Regular and Long-Acting Insulin on Cognition and Alzheimer's Disease Biomarkers: A Pilot Clinical Trial.", "citation": "Craft S, Claxton A, Baker LD et al. Effects of Regular and Long-Acting Insulin on Cognition and Alzheimer's Disease Biomarkers: A Pilot Clinical Trial. Journal of Alzheimer's disease : JAD. 2017.", "doi": "10.3233/JAD-161256", "pmcid": "PMC5409050", "url": "https://pubmed.ncbi.nlm.nih.gov/28372335/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/28372335/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID28372335", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "mixed", "what_it_shows": "In a 36-person four-month trial, regular insulin improves memory while detemir and daily function are null; MRI and CSF-ratio signals accompany regular insulin.", "what_it_does_not_show": "Small groups and outcomes constrain durable inference; a formulation-specific symptomatic response does not identify primary aetiology.", "confounders_present": [ "Small groups and outcomes constrain durable inference; a formulation-specific symptomatic response does not identify primary aetiology." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 52, "pmid": "33719017", "title": "A Phase II, Single-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Therapeutic Efficacy of Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease.", "citation": "Rosenbloom M, Barclay TR, Kashyap B et al. A Phase II, Single-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Therapeutic Efficacy of Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease. Drugs & aging. 2021.", "doi": "10.1007/s40266-021-00845-7", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/33719017/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33719017/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID33719017", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "null", "what_it_shows": "Thirty-five-person glulisine trial shows no cognitive, functional or mood benefit at three/six months.", "what_it_does_not_show": "Enrollment/duration and age imbalance limit precision; no selective neuronal engagement result is provided in the abstract, so this regimen's failure is bounded.", "confounders_present": [ "Enrollment/duration and age imbalance limit precision; no selective neuronal engagement result is provided in the abstract, so this regimen's failure is bounded." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 53, "pmid": "32568367", "title": "Safety, Efficacy, and Feasibility of Intranasal Insulin for the Treatment of Mild Cognitive Impairment and Alzheimer Disease Dementia: A Randomized Clinical Trial.", "citation": "Craft S, Raman R, Chow TW et al. Safety, Efficacy, and Feasibility of Intranasal Insulin for the Treatment of Mild Cognitive Impairment and Alzheimer Disease Dementia: A Randomized Clinical Trial. JAMA neurology. 2020.", "doi": "10.1001/jamaneurol.2020.1840", "pmcid": "PMC7309571", "url": "https://pubmed.ncbi.nlm.nih.gov/32568367/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/32568367/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "SNIFF-NCT01767909", "access_depth": "full_text_partial", "access_note": "Complete primary abstract and linked-status metadata examined. Selected body sections: Methods:Participants, Statistical Analysis; Results:CSF, Secondary Analyses. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "null", "what_it_shows": "SNIFF randomizes 289; the prespecified device2 cohort of 240 has no 12-month ADAS-cog benefit or secondary clinical/CSF benefit, with difference 0.0258 and P=.98.", "what_it_does_not_show": "Original Methods define device2 as primary before lock with serial clinical gatekeeping. Device1 has nominal six-month but nonsignificant twelve-month cognition and greater entorhinal volume loss; device2 has small greater hippocampal loss. Primary CSF insulin is unchanged, leaving delivery/engagement uncertain rather than proving no transient neuronal effect.", "confounders_present": [ "Original Methods define device2 as primary before lock with serial clinical gatekeeping. Device1 has nominal six-month but nonsignificant twelve-month cognition and greater entorhinal volume loss; device2 has small greater hippocampal loss. Primary CSF insulin is unchanged, leaving delivery/engagement uncertain rather than proving no transient neuronal effect." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 54, "pmid": "34101779", "title": "Intranasal Insulin Reduces White Matter Hyperintensity Progression in Association with Improvements in Cognition and CSF Biomarker Profiles in Mild Cognitive Impairment and Alzheimer's Disease.", "citation": "Kellar D, Lockhart SN, Aisen P et al. Intranasal Insulin Reduces White Matter Hyperintensity Progression in Association with Improvements in Cognition and CSF Biomarker Profiles in Mild Cognitive Impairment and Alzheimer's Disease. The journal of prevention of Alzheimer's disease. 2021.", "doi": "10.14283/jpad.2021.14", "pmcid": "PMC10233712", "url": "https://pubmed.ncbi.nlm.nih.gov/34101779/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/34101779/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "SNIFF-NCT01767909", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional secondary analysis", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "In SNIFF's 49-person device1 subgroup, insulin reduces deep/frontal WMH progression associated with clinical and CSF measures.", "what_it_does_not_show": "This is a secondary analysis of the same selected device cohort, not independent trial replication or direct neuronal signalling engagement.", "confounders_present": [ "This is a secondary analysis of the same selected device cohort, not independent trial replication or direct neuronal signalling engagement." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 55, "pmid": "35079029", "title": "Intranasal insulin modulates cerebrospinal fluid markers of neuroinflammation in mild cognitive impairment and Alzheimer's disease: a randomized trial.", "citation": "Kellar D, Register T, Lockhart SN et al. Intranasal insulin modulates cerebrospinal fluid markers of neuroinflammation in mild cognitive impairment and Alzheimer's disease: a randomized trial. Scientific reports. 2022.", "doi": "10.1038/s41598-022-05165-3", "pmcid": "PMC8789895", "url": "https://pubmed.ncbi.nlm.nih.gov/35079029/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/35079029/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "SNIFF-NCT01767909", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional secondary analysis", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "SNIFF's cohort showing benefit has treatment-related CSF IL6, interferon-gamma and eotaxin changes with exploratory clinical/imaging associations.", "what_it_does_not_show": "Selected shared cohort, multiple marker tests and inflammatory rather than neuron-specific engagement limit mechanistic inference; the large primary cohort remains null.", "confounders_present": [ "Selected shared cohort, multiple marker tests and inflammatory rather than neuron-specific engagement limit mechanistic inference; the large primary cohort remains null." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 56, "pmid": "27252647", "title": "In Alzheimer's Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial.", "citation": "Gejl M, Gjedde A, Egefjord L et al. In Alzheimer's Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial. Frontiers in aging neuroscience. 2016.", "doi": "10.3389/fnagi.2016.00108", "pmcid": "PMC4877513", "url": "https://pubmed.ncbi.nlm.nih.gov/27252647/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/27252647/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "Liraglutide-NCT01469351", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "mixed", "what_it_shows": "Thirty-eight-person six-month liraglutide trial reports preserved FDG metabolism but no between-group amyloid effect or cognitive change.", "what_it_does_not_show": "Underpowered cognition and predominantly biomarker effects do not establish clinical trajectory modification; between-arm evidence must be distinguished from within-arm decline.", "confounders_present": [ "Underpowered cognition and predominantly biomarker effects do not establish clinical trajectory modification; between-arm evidence must be distinguished from within-arm decline." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 57, "pmid": "29235507", "title": "Blood-Brain Glucose Transfer in Alzheimer's disease: Effect of GLP-1 Analog Treatment.", "citation": "Gejl M, Brock B, Egefjord L et al. Blood-Brain Glucose Transfer in Alzheimer's disease: Effect of GLP-1 Analog Treatment. Scientific reports. 2017.", "doi": "10.1038/s41598-017-17718-y", "pmcid": "PMC5727512", "url": "https://pubmed.ncbi.nlm.nih.gov/29235507/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/29235507/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "Liraglutide-NCT01469351", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional secondary analysis", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Reanalysis of the same 38-person liraglutide trial estimates increased blood-brain glucose transport capacity relative to placebo.", "what_it_does_not_show": "Model-derived BBB transfer is a distinct downstream endpoint, not direct neuronal IR correction or a second independent clinical trial.", "confounders_present": [ "Model-derived BBB transfer is a distinct downstream endpoint, not direct neuronal IR correction or a second independent clinical trial." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 58, "pmid": "41326666", "title": "Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trial.", "citation": "Edison P, Femminella GD, Ritchie C et al. Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trial. Nature medicine. 2026.", "doi": "10.1038/s41591-025-04106-7", "pmcid": "PMC12823385", "url": "https://pubmed.ncbi.nlm.nih.gov/41326666/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/41326666/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID41326666", "access_depth": "full_text_partial", "access_note": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Results:paragraph0, 1:Results:paragraph15, 1:Results:paragraph17, 1:Results:paragraph19, 1:Results:paragraph20, 1:Results:paragraph22, 1:Results:paragraph24, 3:Methods:paragraph1, 3:Methods:paragraph3, 3:Methods:paragraph5, 3:Methods:paragraph6, 3:Methods:paragraph10, 3:Methods:paragraph12, 3:Methods:paragraph63, 3:Methods:paragraph65, 3:Methods:paragraph66. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "mixed", "what_it_shows": "ELAD randomizes 204 and finds no primary FDG difference or CDR/ADL benefit; ADAS-Exec has an unadjusted secondary signal.", "what_it_does_not_show": "Original Methods use154 complete SUV scans and101 spectral sensitivity scans without outcome imputation; no CSF was collected and planned tau/TSPO PET was not done. Exploratory MRI, weight loss and limited brain-penetration arguments do not directly verify neuronal insulin engagement.", "confounders_present": [ "Original Methods use154 complete SUV scans and101 spectral sensitivity scans without outcome imputation; no CSF was collected and planned tau/TSPO PET was not done. Exploratory MRI, weight loss and limited brain-penetration arguments do not directly verify neuronal insulin engagement." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 59, "pmid": "31518224", "title": "A Pilot Study of Exenatide Actions in Alzheimer's Disease.", "citation": "Mullins RJ, Mustapic M, Chia CW et al. A Pilot Study of Exenatide Actions in Alzheimer's Disease. Current Alzheimer research. 2019.", "doi": "10.2174/1567205016666190913155950", "pmcid": "PMC7476877", "url": "https://pubmed.ncbi.nlm.nih.gov/31518224/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/31518224/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID31518224", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "null", "what_it_shows": "Early-terminated exenatide pilot has 18 completers and no clinical, cognitive, MRI or main fluid response; EV Aβ42 alone falls.", "what_it_does_not_show": "Severe power limitation and disputed neural EV provenance constrain interpretation; isolated EV biomarker improvement is not clinical disease modification.", "confounders_present": [ "Severe power limitation and disputed neural EV provenance constrain interpretation; isolated EV biomarker improvement is not clinical disease modification." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 60, "pmid": "38565814", "title": "Long-acting exenatide does not prevent cognitive decline in mild cognitive impairment: a proof-of-concept clinical trial.", "citation": "Dei Cas A, Micheli MM, Aldigeri R et al. Long-acting exenatide does not prevent cognitive decline in mild cognitive impairment: a proof-of-concept clinical trial. Journal of endocrinological investigation. 2024.", "doi": "10.1007/s40618-024-02320-7", "pmcid": "PMC11368991", "url": "https://pubmed.ncbi.nlm.nih.gov/38565814/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/38565814/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID38565814", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "null", "what_it_shows": "Thirty-two MCI participants randomized to weekly exenatide or no treatment show no ADAS-Cog benefit; weight/glucose fall and a female-worsening interaction is reported.", "what_it_does_not_show": "Small open comparator and subgroup multiplicity limit the interaction; systemic engagement does not demonstrate correction of brain neuronal insulin resistance.", "confounders_present": [ "Small open comparator and subgroup multiplicity limit the interaction; systemic engagement does not demonstrate correction of brain neuronal insulin resistance." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 61, "pmid": "41865758", "title": "Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials.", "citation": "Cummings JL, Atri A, Sano M et al. Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials. Lancet (London, England). 2026.", "doi": "10.1016/S0140-6736(26)00459-9", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/41865758/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/41865758/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID41865758", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "null", "what_it_shows": "EVOKE and EVOKE+ randomize3808 amyloid-confirmed early AD participants; semaglutide does not improve 104-week CDR-SB in either trial, with differences -.08 and +.10.", "what_it_does_not_show": "Primary abstract/status was examined; original numerical body was unavailable. Strong regimen-level clinical negatives do not demonstrate selective restoration of deficient neuronal signalling or refute every earlier metabolic-risk contribution.", "confounders_present": [ "Primary abstract/status was examined; original numerical body was unavailable. Strong regimen-level clinical negatives do not demonstrate selective restoration of deficient neuronal signalling or refute every earlier metabolic-risk contribution." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [ "Two independently randomized trials in one report, sharing sponsor/drug/protocol and broad mechanistic assumptions." ] }, { "n": 62, "pmid": "39445596", "title": "Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US.", "citation": "Wang W, Wang Q, Qi X et al. Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2024.", "doi": "10.1002/alz.14313", "pmcid": "PMC11667504", "url": "https://pubmed.ncbi.nlm.nih.gov/39445596/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/39445596/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID39445596", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3", "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "human observational target-trial emulation", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Matched US diabetes EHR emulations associate semaglutide with lower first AD diagnosis than seven active medication comparators.", "what_it_does_not_show": "Target-trial emulation remains nonrandomized; indication, residual severity/adherence/ascertainment and clinically unrecognized preexisting pathology persist. Prevention in diabetes is a different estimand from EVOKE symptomatic AD.", "confounders_present": [ "Target-trial emulation remains nonrandomized; indication, residual severity/adherence/ascertainment and clinically unrecognized preexisting pathology persist. Prevention in diabetes is a different estimand from EVOKE symptomatic AD." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 63, "pmid": "35229024", "title": "Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers.", "citation": "Nørgaard CH, Friedrich S, Hansen CT et al. Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers. Alzheimer's & dementia (New York, N. Y.). 2022.", "doi": "10.1002/trc2.12268", "pmcid": "PMC8864443", "url": "https://pubmed.ncbi.nlm.nih.gov/35229024/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/35229024/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID35229024", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3", "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "pooled randomized trials and human observational", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "Pooled diabetes cardiovascular trials and Danish prescriptions both show lower recorded dementia with GLP1RA exposure; randomized estimate HR=.47.", "what_it_does_not_show": "Random allocation deserves causal credit for this ancillary dementia outcome, not dismissal as observational. Endpoint capture, mixed source classes and systemic/vascular effects do not identify neuronal insulin mediation or established AD progression.", "confounders_present": [ "Random allocation deserves causal credit for this ancillary dementia outcome, not dismissal as observational. Endpoint capture, mixed source classes and systemic/vascular effects do not identify neuronal insulin mediation or established AD progression." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [ "Three cardiovascular trials and a Danish registry are different evidence classes within one report." ] }, { "n": 64, "pmid": "20733306", "title": "Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study.", "citation": "Gold M, Alderton C, Zvartau-Hind M et al. Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study. Dementia and geriatric cognitive disorders. 2010.", "doi": "10.1159/000318845", "pmcid": "PMC3214882", "url": "https://pubmed.ncbi.nlm.nih.gov/20733306/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/20733306/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID20733306", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "null", "what_it_shows": "693-person rosiglitazone monotherapy phase3 trial fails prespecified cognition/global endpoints overall and in prospectively stratified APOE4-negative participants.", "what_it_does_not_show": "Failure of this dose/PPAR regimen is not proof of an engaged neuronal IR defect's irrelevance; the earlier genotype rescue prediction did not replicate.", "confounders_present": [ "Failure of this dose/PPAR regimen is not proof of an engaged neuronal IR defect's irrelevance; the earlier genotype rescue prediction did not replicate." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 65, "pmid": "21592048", "title": "Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies.", "citation": "Harrington C, Sawchak S, Chiang C et al. Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies. Current Alzheimer research. 2011.", "doi": "10.2174/156720511796391935", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/21592048/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/21592048/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID21592048", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "null", "what_it_shows": "Two rosiglitazone adjunct phase3 trials of 1496 and 1485 participants fail 48-week cognition/global endpoints with no APOE interaction.", "what_it_does_not_show": "Two trials in one report strengthen clinical nonreplication, while PPAR pleiotropy and uncertain brain exposure prevent a universal insulin-mechanism exclusion.", "confounders_present": [ "Two trials in one report strengthen clinical nonreplication, while PPAR pleiotropy and uncertain brain exposure prevent a universal insulin-mechanism exclusion." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [ "Two independent adjunct trials in one report, sharing sponsor/drug and programme." ] }, { "n": 66, "pmid": "34146512", "title": "Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial.", "citation": "Burns DK, Alexander RC, Welsh-Bohmer KA et al. Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Neurology. 2021.", "doi": "10.1016/S1474-4422(21)00043-0", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/34146512/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/34146512/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID34146512", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3", "SC4" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "null", "what_it_shows": "TOMMORROW enrolls 3494 cognitively healthy participants; low-dose pioglitazone does not delay MCI and the trial stops for futility.", "what_it_does_not_show": "0.8 mg regimen, incomplete event accrual and genetic-risk selection constrain prevention inference; the risk algorithm also misses its prespecified significance threshold and neuronal engagement is not established.", "confounders_present": [ "0.8 mg regimen, incomplete event accrual and genetic-risk selection constrain prevention inference; the risk algorithm also misses its prespecified significance threshold and neuronal engagement is not established." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 67, "pmid": "26890736", "title": "Metformin in Amnestic Mild Cognitive Impairment: Results of a Pilot Randomized Placebo Controlled Clinical Trial.", "citation": "Luchsinger JA, Perez T, Chang H et al. Metformin in Amnestic Mild Cognitive Impairment: Results of a Pilot Randomized Placebo Controlled Clinical Trial. Journal of Alzheimer's disease : JAD. 2016.", "doi": "10.3233/JAD-150493", "pmcid": "PMC5079271", "url": "https://pubmed.ncbi.nlm.nih.gov/26890736/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/26890736/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID26890736", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "mixed", "what_it_shows": "In 80 overweight/obese aMCI adults without treated diabetes, metformin improves one adjusted recall outcome but not ADAS-cog or other endpoints.", "what_it_does_not_show": "Baseline imbalance, low maximal-dose tolerability, multiple endpoints and no neuron-specific target engagement limit disease-modification inference.", "confounders_present": [ "Baseline imbalance, low maximal-dose tolerability, multiple endpoints and no neuron-specific target engagement limit disease-modification inference." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 68, "pmid": "41057918", "title": "A phase 2A/B randomized trial of metabolic modulators intranasal insulin and empagliflozin for MCI and early AD.", "citation": "Erichsen JM, Register TC, Sutphen C et al. A phase 2A/B randomized trial of metabolic modulators intranasal insulin and empagliflozin for MCI and early AD. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2025.", "doi": "10.1002/alz.70704", "pmcid": "PMC12504051", "url": "https://pubmed.ncbi.nlm.nih.gov/41057918/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/41057918/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID41057918", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Four-week factorial insulin/empagliflozin trial meets safety aims and reports promising secondary cognition, perfusion and fluid-marker changes.", "what_it_does_not_show": "Primary outcome is adverse events; short duration and secondary outcomes require larger longer confirmation. Empagliflozin vascular/systemic effects and fluid changes do not identify neuronal initiating resistance.", "confounders_present": [ "Primary outcome is adverse events; short duration and secondary outcomes require larger longer confirmation. Empagliflozin vascular/systemic effects and fluid changes do not identify neuronal initiating resistance." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] } ], "verification_summary": { "load_bearing_claims_checked": 73, "verified": 73, "unverified": 0, "contradicted": 0, "note": "Verified attribution is distinct from mechanism truth or complete body access." }, "factual_issues_found": [], "cap_rules_applied": [], "cap_precedence_resolutions": [ { "collision": "Perturbation in a defined setting versus broader inference", "subclaim_scope_cap_binds_on": "Primary dysfunction of neuronal insulin/IGF-1 signalling initiates and drives sporadic Alzheimer's disease, and correcting this dysfunction modifies the disease trajectory.", "subclaim_scope_threshold_binds_on": "The precise experimentally tested subclaim scope", "resolution": "The exact index primary rubric06 is retained with neurodegeneration01 co-governing. AD functional trajectory is the disease-specific healthspan analogue; FDG, phosphorylation, stress resistance and brief cognition alone do not establish modification. Evidence labels use rubric01 Strong for adequately randomized hard clinical regimen tests, including negatives; they are not positive Strong causal proof of neuronal mediation. Adult conditional and pathway-rescue experiments are credited within their systems, with single-background/pleiotropy limits. Cross-species direction discrimination, human functional assays, genetic instruments and several drug classes are evaluated together, not re-capped by one weak leg. Insulin and IGF branches have nonconcordant directions; the human instruments and drug effects do not selectively measure the claimed neuronal initiating exposure.", "note": "Convergent lines are assessed as a set; one weak leg is not re-capped over the assembled case." } ], "boundary_check_BGD": [ { "subclaim_id": "SC1", "field_valid_perturbation_quote": "\n- Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension\n- Must separate developmental effects from true aging effects\n- Biomarker change alone does NOT satisfy this threshold", "qualifying_evidence_present": "no", "qualifying_evidence_citation": "PMID22476197, PMID32557841, PMID34092791, PMID38868956, PMID40210837", "gamma_hard_rules_triggered": [ "Functional postmortem response establishes a scoped finding, not disease trajectory." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "no", "perturbation_result_note": "Functional postmortem challenge supports insulin/IGF resistance in selected AD hippocampal samples without diabetes, beyond static marker abundance. Other region/site assays are null or show higher downstream AKT activity. Γ records support for this finding within the causal review; it does not deny the observed functional resistance. No disease-trajectory crossing is inferred from tissue responsiveness alone.", "ceiling_from_boundary_check": "Γ" }, { "subclaim_id": "SC2", "field_valid_perturbation_quote": "\n- Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension\n- Must separate developmental effects from true aging effects\n- Biomarker change alone does NOT satisfy this threshold", "qualifying_evidence_present": "yes", "qualifying_evidence_citation": "PMID14981233, PMID12904469, PMID11000114, PMID26290229, PMID19487308, PMID20005808, PMID28652303, PMID22476196, PMID24315369, PMID19188609, PMID25543463, PMID28302722, PMID30652125, PMID22661254, PMID31915254, PMID28595357, PMID25617315, PMID29664737, PMID29398615, PMID40388612, PMID33291072, PMID20110613, PMID27173425, PMID37730113, PMID24918340, PMID15288712", "gamma_hard_rules_triggered": [ "Defined functional causal effects cross the narrow boundary; species/branch/cell specificity limits extrapolation." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "yes", "perturbation_result_note": "Loss, rescue and pathway support affect synaptic or cognitive function in defined models, reaching constrained causal contribution. Adult glial deletions demonstrate cell-type differences and neuronal PTP1B/GLP1 manipulations protect disease-model function. The IR and IGF branches cannot be merged: neuronal IGF attenuation can instead be protective, and selective adult neuronal IR mediation remains incompletely isolated.", "ceiling_from_boundary_check": "Δ or higher" }, { "subclaim_id": "SC3", "field_valid_perturbation_quote": "\n- Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension\n- Must separate developmental effects from true aging effects\n- Biomarker change alone does NOT satisfy this threshold", "qualifying_evidence_present": "no", "qualifying_evidence_citation": "PMID22476197, PMID32557841, PMID34092791, PMID38868956, PMID40210837, PMID14981233, PMID12904469, PMID11000114, PMID26290229, PMID19487308, PMID20005808, PMID28652303, PMID22476196, PMID24315369, PMID19188609, PMID25543463, PMID28302722, PMID30652125, PMID31915254, PMID28595357, PMID25617315, PMID40388612, PMID33291072, PMID20110613, PMID27173425, PMID39479764, PMID39350373, PMID26650880, PMID35229024, PMID34146512", "gamma_hard_rules_triggered": [ "Preclinical symptoms are not prelesion temporal order; no selective initiating neuronal mediator instrument." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "no", "perturbation_result_note": "Primary upstream failure remains a mechanistic possibility supported by imposed metabolic injury and antecedent peripheral/putative EV clues, but no selective neuronal instrument or serial preamyloid/tau functional assay establishes sporadic human order. Models demonstrate the opposite direction as well. Γ is an unmet positive primacy burden, not a blanket observational cap imposed on the entire convergent set.", "ceiling_from_boundary_check": "Γ" }, { "subclaim_id": "SC4", "field_valid_perturbation_quote": "\n- Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension\n- Must separate developmental effects from true aging effects\n- Biomarker change alone does NOT satisfy this threshold", "qualifying_evidence_present": "no", "qualifying_evidence_citation": "PMID37730113, PMID24918340, PMID15288712, PMID27553192, PMID40703476, PMID17942819, PMID21911655, PMID25374101, PMID28372335, PMID33719017, PMID32568367, PMID27252647, PMID41326666, PMID31518224, PMID38565814, PMID41865758, PMID35229024, PMID20733306, PMID21592048, PMID34146512, PMID26890736, PMID41057918", "gamma_hard_rules_triggered": [ "No reproducible target-engaged clinical modification across regimens; biomarkers and short symptomatic effects remain separate." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "no", "perturbation_result_note": "Small insulin/metformin and recent short factorial trials show scoped clinical signals, but larger insulin, rosiglitazone, pioglitazone and GLP1 trials do not establish reproducible disease modification. SNIFF delivery uncertainty and pleiotropic/systemic engagement prevent interpreting failed regimens as a universal negative neuronal mechanism test. ELAD secondary cognition is unadjusted and EVOKE clinical outcomes are null.", "ceiling_from_boundary_check": "Γ" } ], "thresholds_tested": [ { "subclaim_id": "SC1", "threshold": "Δ", "requirement_quoted": "Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.", "satisfied": "no", "supporting_evidence": [ "[2] AD hippocampal tissue without diabetes responds less to insulin and IGF challenge; IRS1 serine measures associate with cognition and pathology.", "[3] In 150 matched ROS brains, IRS1 measures and ex-vivo response were not associated with global AD pathology; higher AKT phosphorylation was associated with pathology and lower cognition.", "[10] Orthogonal biofluid fractionation and single-molecule assays find L1CAM largely outside extracellular vesicles, challenging common neuronal immunocapture assumptions.", "[11] Single-EV methods find L1CAM epitopes co-expressed with neuronal proteins and enrichment relative to L1CAM-negative EVs.", "[12] Across plasma, CSF and induced-neuron media, generic EVs and neuronal cargo are recovered but L1CAM predominantly remains free and is not enriched by immunocapture." ], "what_would_cross_it": "Independently replicate cell-resolved ante-mortem and ex-vivo insulin-response assays with region, phosphorylation-site, vascular and peripheral-metabolic controls, then connect resistance to selective functional rescue." }, { "subclaim_id": "SC2", "threshold": "Δ", "requirement_quoted": "Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.", "satisfied": "yes", "supporting_evidence": [ "[13] NIRKO loses insulin-mediated signalling and increases tau phosphorylation while showing no neuronal survival, memory or basal brain glucose deficit.", "[14] Global IRS2 loss reduces developmental neuronal proliferation and older mice accumulate phosphorylated tau pathology.", "[15] Neural insulin-receptor deletion alters feeding, obesity and reproductive control without altered brain development or neuronal survival.", "[16] Adult neuron-specific IGF1R deletion in APP/PS1 mice improves spatial memory and reduces amyloid/inflammation, with neuronal structural changes and higher plasma amyloid.", "[17] IRS2 or neuronal IGF1R loss reduces amyloid and prevents premature Tg2576 death; neuronal IR loss does not alter lethality.", "[18] Reduced IGF signalling protects AD-model mice against behavioural deficits, inflammation and neuronal loss while promoting dense amyloid aggregates.", "[19] Tau deletion impairs hippocampal insulin response through IRS1/PTEN and changes hypothalamic insulin effects; human tau haplotypes associate with glycemic traits.", "[20] Amyloid oligomers activate JNK/TNF, inhibit IRS1 signalling in neurons and primate challenge, while exendin4 restores neuronal transport and improves transgenic-mouse cognition.", "[21] TNFR1/PKR disruption blocks oligomer-induced translation-signalling changes and memory impairment; insulin support rescues pathway abnormalities.", "[22] Insulin prevents oligomer-induced surface IR loss, oxidative stress and spine deterioration; kinase inhibition abolishes protection and rosiglitazone potentiates it.", "[23] Active AKT, GSK3 inhibition and exendin4 prevent or reverse oligomer-induced BDNF transport deficits in wild-type and tau-null neurons.", "[24] Oligomers transiently inhibit AMPK/ATP and remove dendritic glucose transporters; NMDA-related intervention and insulin protect these measures.", "[25] Reducing fly insulin signalling suppresses expressed-Aβ toxicity; Aβ elevates brain insulin signalling while peripheral signalling falls.", "[26] IR beta-subunit haploinsufficiency impairs late LTP and recognition memory.", "[27] Neuronal PTP1B ablation and systemic trodusquemine prevent neuron loss and spatial memory deficits in hAPP-J20 mice; neuronal ablation preserves benefit without reducing inflammation.", "[28] Adult neuronal IGF1R suppression protects against oligomer-induced memory and inflammatory injury; related APP/PS1 transcriptional signatures converge.", "[29] Central, but not systemic, oligomer infusion induces peripheral glucose intolerance; TNFR1 loss and central inflammatory/ER-stress inhibition prevent it.", "[30] Astrocyte IR deletion alters ATP exocytosis and dopamine-related behaviour; central ATP analog rescues depressive-like behaviour.", "[31] Inducible astrocyte IGFR loss impairs working memory, mitochondrial function and glucose/amyloid uptake.", "[32] Inducible microglial IR loss impairs amyloid uptake and increases plaque/inflammation in 5xFAD, with mood/social changes.", "[33] Prolonged high-fat diet worsens cognition and soluble amyloid in APP/PS1 mice while central and peripheral transporter responses differ.", "[34] Intracerebroventricular STZ worsens Tg2576 spatial cognition, mortality and amyloid/tau measures.", "[35] Induced diabetes increases subicular amyloid plaques in middle-aged 3xTg mice but does not worsen learning/memory or AT8 burden.", "[43] Semaglutide improves short-term cognition and glucose/pathology measures in 3xTg mice; SIRT1 inhibition blocks cultured metabolic effects.", "[44] Seven-day intranasal insulin in 3xTg mice restores signalling/synaptic proteins and lowers Aβ40 and microglial activation.", "[45] In 38 healthy participants, eight-week intranasal insulin improves delayed recall without plasma insulin/glucose change." ], "what_would_cross_it": "" }, { "subclaim_id": "SC2", "threshold": "Ε", "requirement_quoted": "Requires causal effect in constrained contexts, backgrounds, or species.", "satisfied": "yes", "supporting_evidence": [ "[13] NIRKO loses insulin-mediated signalling and increases tau phosphorylation while showing no neuronal survival, memory or basal brain glucose deficit.", "[14] Global IRS2 loss reduces developmental neuronal proliferation and older mice accumulate phosphorylated tau pathology.", "[15] Neural insulin-receptor deletion alters feeding, obesity and reproductive control without altered brain development or neuronal survival.", "[16] Adult neuron-specific IGF1R deletion in APP/PS1 mice improves spatial memory and reduces amyloid/inflammation, with neuronal structural changes and higher plasma amyloid.", "[17] IRS2 or neuronal IGF1R loss reduces amyloid and prevents premature Tg2576 death; neuronal IR loss does not alter lethality.", "[18] Reduced IGF signalling protects AD-model mice against behavioural deficits, inflammation and neuronal loss while promoting dense amyloid aggregates.", "[19] Tau deletion impairs hippocampal insulin response through IRS1/PTEN and changes hypothalamic insulin effects; human tau haplotypes associate with glycemic traits.", "[20] Amyloid oligomers activate JNK/TNF, inhibit IRS1 signalling in neurons and primate challenge, while exendin4 restores neuronal transport and improves transgenic-mouse cognition.", "[21] TNFR1/PKR disruption blocks oligomer-induced translation-signalling changes and memory impairment; insulin support rescues pathway abnormalities.", "[22] Insulin prevents oligomer-induced surface IR loss, oxidative stress and spine deterioration; kinase inhibition abolishes protection and rosiglitazone potentiates it.", "[23] Active AKT, GSK3 inhibition and exendin4 prevent or reverse oligomer-induced BDNF transport deficits in wild-type and tau-null neurons.", "[24] Oligomers transiently inhibit AMPK/ATP and remove dendritic glucose transporters; NMDA-related intervention and insulin protect these measures.", "[25] Reducing fly insulin signalling suppresses expressed-Aβ toxicity; Aβ elevates brain insulin signalling while peripheral signalling falls.", "[26] IR beta-subunit haploinsufficiency impairs late LTP and recognition memory.", "[27] Neuronal PTP1B ablation and systemic trodusquemine prevent neuron loss and spatial memory deficits in hAPP-J20 mice; neuronal ablation preserves benefit without reducing inflammation.", "[28] Adult neuronal IGF1R suppression protects against oligomer-induced memory and inflammatory injury; related APP/PS1 transcriptional signatures converge.", "[29] Central, but not systemic, oligomer infusion induces peripheral glucose intolerance; TNFR1 loss and central inflammatory/ER-stress inhibition prevent it.", "[30] Astrocyte IR deletion alters ATP exocytosis and dopamine-related behaviour; central ATP analog rescues depressive-like behaviour.", "[31] Inducible astrocyte IGFR loss impairs working memory, mitochondrial function and glucose/amyloid uptake.", "[32] Inducible microglial IR loss impairs amyloid uptake and increases plaque/inflammation in 5xFAD, with mood/social changes.", "[33] Prolonged high-fat diet worsens cognition and soluble amyloid in APP/PS1 mice while central and peripheral transporter responses differ.", "[34] Intracerebroventricular STZ worsens Tg2576 spatial cognition, mortality and amyloid/tau measures.", "[35] Induced diabetes increases subicular amyloid plaques in middle-aged 3xTg mice but does not worsen learning/memory or AT8 burden.", "[43] Semaglutide improves short-term cognition and glucose/pathology measures in 3xTg mice; SIRT1 inhibition blocks cultured metabolic effects.", "[44] Seven-day intranasal insulin in 3xTg mice restores signalling/synaptic proteins and lowers Aβ40 and microglial activation.", "[45] In 38 healthy participants, eight-week intranasal insulin improves delayed recall without plasma insulin/glucose change." ], "what_would_cross_it": "" }, { "subclaim_id": "SC2", "threshold": "Ζ", "requirement_quoted": "Requires:\n- Reproducible intervention effects\n- Mechanistic narrowing\n- Evidence not reducible to general sickness, caloric reduction, or developmental artifacts", "satisfied": "no", "supporting_evidence": [ "[13] NIRKO loses insulin-mediated signalling and increases tau phosphorylation while showing no neuronal survival, memory or basal brain glucose deficit.", "[14] Global IRS2 loss reduces developmental neuronal proliferation and older mice accumulate phosphorylated tau pathology.", "[15] Neural insulin-receptor deletion alters feeding, obesity and reproductive control without altered brain development or neuronal survival.", "[16] Adult neuron-specific IGF1R deletion in APP/PS1 mice improves spatial memory and reduces amyloid/inflammation, with neuronal structural changes and higher plasma amyloid.", "[17] IRS2 or neuronal IGF1R loss reduces amyloid and prevents premature Tg2576 death; neuronal IR loss does not alter lethality.", "[18] Reduced IGF signalling protects AD-model mice against behavioural deficits, inflammation and neuronal loss while promoting dense amyloid aggregates.", "[19] Tau deletion impairs hippocampal insulin response through IRS1/PTEN and changes hypothalamic insulin effects; human tau haplotypes associate with glycemic traits.", "[20] Amyloid oligomers activate JNK/TNF, inhibit IRS1 signalling in neurons and primate challenge, while exendin4 restores neuronal transport and improves transgenic-mouse cognition.", "[21] TNFR1/PKR disruption blocks oligomer-induced translation-signalling changes and memory impairment; insulin support rescues pathway abnormalities.", "[22] Insulin prevents oligomer-induced surface IR loss, oxidative stress and spine deterioration; kinase inhibition abolishes protection and rosiglitazone potentiates it.", "[23] Active AKT, GSK3 inhibition and exendin4 prevent or reverse oligomer-induced BDNF transport deficits in wild-type and tau-null neurons.", "[24] Oligomers transiently inhibit AMPK/ATP and remove dendritic glucose transporters; NMDA-related intervention and insulin protect these measures.", "[25] Reducing fly insulin signalling suppresses expressed-Aβ toxicity; Aβ elevates brain insulin signalling while peripheral signalling falls.", "[26] IR beta-subunit haploinsufficiency impairs late LTP and recognition memory.", "[27] Neuronal PTP1B ablation and systemic trodusquemine prevent neuron loss and spatial memory deficits in hAPP-J20 mice; neuronal ablation preserves benefit without reducing inflammation.", "[28] Adult neuronal IGF1R suppression protects against oligomer-induced memory and inflammatory injury; related APP/PS1 transcriptional signatures converge.", "[29] Central, but not systemic, oligomer infusion induces peripheral glucose intolerance; TNFR1 loss and central inflammatory/ER-stress inhibition prevent it.", "[30] Astrocyte IR deletion alters ATP exocytosis and dopamine-related behaviour; central ATP analog rescues depressive-like behaviour.", "[31] Inducible astrocyte IGFR loss impairs working memory, mitochondrial function and glucose/amyloid uptake.", "[32] Inducible microglial IR loss impairs amyloid uptake and increases plaque/inflammation in 5xFAD, with mood/social changes.", "[33] Prolonged high-fat diet worsens cognition and soluble amyloid in APP/PS1 mice while central and peripheral transporter responses differ.", "[34] Intracerebroventricular STZ worsens Tg2576 spatial cognition, mortality and amyloid/tau measures.", "[35] Induced diabetes increases subicular amyloid plaques in middle-aged 3xTg mice but does not worsen learning/memory or AT8 burden.", "[43] Semaglutide improves short-term cognition and glucose/pathology measures in 3xTg mice; SIRT1 inhibition blocks cultured metabolic effects.", "[44] Seven-day intranasal insulin in 3xTg mice restores signalling/synaptic proteins and lowers Aβ40 and microglial activation.", "[45] In 38 healthy participants, eight-week intranasal insulin improves delayed recall without plasma insulin/glucose change." ], "what_would_cross_it": "Adult neuronal IR-specific loss and restoration with receptor epistasis change disease-model function in independent backgrounds while controlling intake, vascular/metabolic effects and IGF branch direction." }, { "subclaim_id": "SC3", "threshold": "Δ", "requirement_quoted": "Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.", "satisfied": "no", "supporting_evidence": [ "[2] AD hippocampal tissue without diabetes responds less to insulin and IGF challenge; IRS1 serine measures associate with cognition and pathology.", "[3] In 150 matched ROS brains, IRS1 measures and ex-vivo response were not associated with global AD pathology; higher AKT phosphorylation was associated with pathology and lower cognition.", "[10] Orthogonal biofluid fractionation and single-molecule assays find L1CAM largely outside extracellular vesicles, challenging common neuronal immunocapture assumptions.", "[11] Single-EV methods find L1CAM epitopes co-expressed with neuronal proteins and enrichment relative to L1CAM-negative EVs.", "[12] Across plasma, CSF and induced-neuron media, generic EVs and neuronal cargo are recovered but L1CAM predominantly remains free and is not enriched by immunocapture.", "[13] NIRKO loses insulin-mediated signalling and increases tau phosphorylation while showing no neuronal survival, memory or basal brain glucose deficit.", "[14] Global IRS2 loss reduces developmental neuronal proliferation and older mice accumulate phosphorylated tau pathology.", "[15] Neural insulin-receptor deletion alters feeding, obesity and reproductive control without altered brain development or neuronal survival.", "[16] Adult neuron-specific IGF1R deletion in APP/PS1 mice improves spatial memory and reduces amyloid/inflammation, with neuronal structural changes and higher plasma amyloid.", "[17] IRS2 or neuronal IGF1R loss reduces amyloid and prevents premature Tg2576 death; neuronal IR loss does not alter lethality.", "[18] Reduced IGF signalling protects AD-model mice against behavioural deficits, inflammation and neuronal loss while promoting dense amyloid aggregates.", "[19] Tau deletion impairs hippocampal insulin response through IRS1/PTEN and changes hypothalamic insulin effects; human tau haplotypes associate with glycemic traits.", "[20] Amyloid oligomers activate JNK/TNF, inhibit IRS1 signalling in neurons and primate challenge, while exendin4 restores neuronal transport and improves transgenic-mouse cognition.", "[21] TNFR1/PKR disruption blocks oligomer-induced translation-signalling changes and memory impairment; insulin support rescues pathway abnormalities.", "[22] Insulin prevents oligomer-induced surface IR loss, oxidative stress and spine deterioration; kinase inhibition abolishes protection and rosiglitazone potentiates it.", "[23] Active AKT, GSK3 inhibition and exendin4 prevent or reverse oligomer-induced BDNF transport deficits in wild-type and tau-null neurons.", "[24] Oligomers transiently inhibit AMPK/ATP and remove dendritic glucose transporters; NMDA-related intervention and insulin protect these measures.", "[25] Reducing fly insulin signalling suppresses expressed-Aβ toxicity; Aβ elevates brain insulin signalling while peripheral signalling falls.", "[27] Neuronal PTP1B ablation and systemic trodusquemine prevent neuron loss and spatial memory deficits in hAPP-J20 mice; neuronal ablation preserves benefit without reducing inflammation.", "[28] Adult neuronal IGF1R suppression protects against oligomer-induced memory and inflammatory injury; related APP/PS1 transcriptional signatures converge.", "[29] Central, but not systemic, oligomer infusion induces peripheral glucose intolerance; TNFR1 loss and central inflammatory/ER-stress inhibition prevent it.", "[32] Inducible microglial IR loss impairs amyloid uptake and increases plaque/inflammation in 5xFAD, with mood/social changes.", "[33] Prolonged high-fat diet worsens cognition and soluble amyloid in APP/PS1 mice while central and peripheral transporter responses differ.", "[34] Intracerebroventricular STZ worsens Tg2576 spatial cognition, mortality and amyloid/tau measures.", "[35] Induced diabetes increases subicular amyloid plaques in middle-aged 3xTg mice but does not worsen learning/memory or AT8 burden.", "[40] Genetically higher peripheral insulin sensitivity associates with lower AD risk in two outcome datasets, with attenuation after adjusting for T2D.", "[41] Large T2D genetic instruments do not show an AD effect in the primary or FinnGen analysis.", "[42] Overall T2D polygenic liability is null for AD, while a mechanism-specific insulin-sensitivity score predicts AD risk in IGAP.", "[63] Pooled diabetes cardiovascular trials and Danish prescriptions both show lower recorded dementia with GLP1RA exposure; randomized estimate HR=.47.", "[66] TOMMORROW enrolls 3494 cognitively healthy participants; low-dose pioglitazone does not delay MCI and the trial stops for futility." ], "what_would_cross_it": "Prospective functional neuronal signalling before amyloid/tau, or a neuron-selective genetic/natural instrument, predicts and mediates AD initiation independently of systemic and vascular routes." }, { "subclaim_id": "SC4", "threshold": "Δ", "requirement_quoted": "Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.", "satisfied": "no", "supporting_evidence": [ "[43] Semaglutide improves short-term cognition and glucose/pathology measures in 3xTg mice; SIRT1 inhibition blocks cultured metabolic effects.", "[44] Seven-day intranasal insulin in 3xTg mice restores signalling/synaptic proteins and lowers Aβ40 and microglial activation.", "[45] In 38 healthy participants, eight-week intranasal insulin improves delayed recall without plasma insulin/glucose change.", "[46] With the tested Aero Pump lispro regimen, human CSF drug is below quantification despite detection in beagle CSF.", "[47] Intranasal radiolabelled insulin with an Aptar device reaches multiple brain regions in 16 older CN/MCI participants.", "[48] Twenty-one-day randomized insulin pilot improves delayed recall, attention and caregiver function in 25 early AD/MCI participants without changed fasting insulin/glucose.", "[49] Four-month 104-person pilot finds improved delayed memory at 20 IU and preserved caregiver function at both doses, with exploratory FDG and CSF correlations.", "[50] In a 60-person 21-day detemir trial, high-dose memory effects differ by APOE, with improvement in carriers and worsening in noncarriers; daily function is null.", "[51] In a 36-person four-month trial, regular insulin improves memory while detemir and daily function are null; MRI and CSF-ratio signals accompany regular insulin.", "[52] Thirty-five-person glulisine trial shows no cognitive, functional or mood benefit at three/six months.", "[53] SNIFF randomizes 289; the prespecified device2 cohort of 240 has no 12-month ADAS-cog benefit or secondary clinical/CSF benefit, with difference 0.0258 and P=.98.", "[56] Thirty-eight-person six-month liraglutide trial reports preserved FDG metabolism but no between-group amyloid effect or cognitive change.", "[58] ELAD randomizes 204 and finds no primary FDG difference or CDR/ADL benefit; ADAS-Exec has an unadjusted secondary signal.", "[59] Early-terminated exenatide pilot has 18 completers and no clinical, cognitive, MRI or main fluid response; EV Aβ42 alone falls.", "[60] Thirty-two MCI participants randomized to weekly exenatide or no treatment show no ADAS-Cog benefit; weight/glucose fall and a female-worsening interaction is reported.", "[61] EVOKE and EVOKE+ randomize3808 amyloid-confirmed early AD participants; semaglutide does not improve 104-week CDR-SB in either trial, with differences -.08 and +.10.", "[63] Pooled diabetes cardiovascular trials and Danish prescriptions both show lower recorded dementia with GLP1RA exposure; randomized estimate HR=.47.", "[64] 693-person rosiglitazone monotherapy phase3 trial fails prespecified cognition/global endpoints overall and in prospectively stratified APOE4-negative participants.", "[65] Two rosiglitazone adjunct phase3 trials of 1496 and 1485 participants fail 48-week cognition/global endpoints with no APOE interaction.", "[66] TOMMORROW enrolls 3494 cognitively healthy participants; low-dose pioglitazone does not delay MCI and the trial stops for futility.", "[67] In 80 overweight/obese aMCI adults without treated diabetes, metformin improves one adjusted recall outcome but not ADAS-cog or other endpoints.", "[68] Four-week factorial insulin/empagliflozin trial meets safety aims and reports promising secondary cognition, perfusion and fluid-marker changes." ], "what_would_cross_it": "A sufficiently powered biomarker-confirmed trial with validated brain delivery and neuronal pathway engagement demonstrates replicated durable cognition and daily-function benefit, with multiplicity and disease-versus-symptomatic outcomes specified." } ], "generalization_check": { "generalization_tested": "yes", "context_boundary_mapped": "yes", "internal_negative_controls": [ "Insulin dose/low-PMI validation and glutamate uptake positive control.", "Matched diabetes-free versus diabetic tissue and region/site assay comparison.", "Adult conditional versus developmental deletion and IR versus IGF branch contrast.", "Neuronal versus astrocytic/microglial effects, peripheral versus central oligomer routes.", "STZ marker increase with unchanged function.", "EV detergent/isotype/free-protein, tetraspanin, calnexin and non-neuronal media controls.", "Prespecified randomized placebo, serial outcome gatekeeping and device-cohort distinction.", "Prospective APOE stratification after an exploratory genotype signal." ], "note": "Results depend on signalling branch, cell type, developmental timing, transgenic substrate, diet, drug exposure and delivery device. Diabetes prevention, established amyloid-confirmed AD progression and acute healthy memory are different clinical estimands. No uniform insulin-dependent glucose-uptake deficit or single neuron-specific initiating route is demonstrated across this scope." }, "falsification_patterns_met": [ { "pattern": "Signalling loss does not produce AD-like functional degeneration", "evidence": "NIRKO preserves survival/memory and basal glucose despite tau changes; neuronal IR loss does not alter Tg2576 mortality.", "downgrade_applied": false, "note": "Already incorporated into specificity and primacy limits, not applied twice." }, { "pattern": "Reduced IGF signalling protects rather than harms", "evidence": "Adult neuronal deletion, Tg2576 and proteotoxicity mice, plus fly insulin reduction, oppose a uniformly deficient-signalling model.", "downgrade_applied": false, "note": "Branch/cell-specific contradiction constrains the bundled claim." }, { "pattern": "Large therapeutic predictions fail", "evidence": "SNIFF primary cohort, rosiglitazone phase3, TOMMORROW, ELAD FDG and EVOKE cognition are null; small secondary signals do not replace primary outcomes.", "downgrade_applied": false, "note": "These are bounded regimen failures, not proof of no metabolic contribution." } ], "pitfalls_flagged": [ { "pitfall": "Peripheral HOMA/MR relabelled neuronal insulin resistance", "where": "Risk cohorts and glycemic instruments." }, { "pitfall": "Prediagnosis timing relabelled preamyloid/tau initiation", "where": "EV and peripheral biomarker cohorts." }, { "pitfall": "Insulin and IGF branches or neurons and glia collapsed", "where": "Genetic interventions with opposing directions." }, { "pitfall": "FDG or plasma marker change treated as neuronal receptor engagement", "where": "GLP1 trials and metabolic scans." }, { "pitfall": "Shared selected device cohort counted as new efficacy replication", "where": "SNIFF WMH and CSF follow-ups." }, { "pitfall": "Exploratory or nominal secondary outcome replaces a null primary", "where": "Device1, ELAD MRI/cognition and small pilots." }, { "pitfall": "Developmental or STZ injury treated as endogenous aging/AD", "where": "Global IRS2 and toxic challenge models." } ], "causal_tally_audit": { "tally_claimed_by_document": 53, "tally_after_audit": 53, "items_rejected": [ "Null and negative contrasts are discriminators, not positive threshold crossings. Reports and replications are not independent causal lines.", "Assay controls and clinical nulls are discriminators, not positive neuronal causal threshold crossings.", "Two trials in one report and follow-up outcomes are reported explicitly rather than inflated counts." ] }, "steelman": { "case_one_rung_higher": "Δ for the complete claim would require at least one selective endogenous/equivalent initiating neuronal intervention with meaningful trajectory change and credible clinical correction. Functional models and ancillary dementia prevention are real, but do not identify that same mediator or temporal role.", "case_one_rung_lower": "Β would undercredit the assembled pathway perturbations, adult/cell genetic contrasts, ex-vivo functional challenge and human randomized signals. The model is more than a glucose-colocalization narrative, even though its primary human interpretation remains unestablished.", "which_rejected": "Γ retains mechanistic plausibility while separating an Ε constrained contribution from the unestablished primacy/application bundle. It neither equates AD with peripheral diabetes nor declares every insulin-related contribution absent.", "blocking_cap_threshold_or_missing_experiment": "Missing experiment: Predefine an amyloid/tau-negative sporadic-risk cohort with validated live neuron-specific insulin-response measurements; triangulate a selective neuronal exposure instrument and an early CNS-delivered intervention that corrects that response, with matched adult conditional model loss/rescue and repeated pathology/function follow-up." }, "final_score": { "hsef_level": "Γ", "hsef_descriptor": "Mechanistically plausible, partial system support", "confidence": "Moderate", "confidence_rationale": "68 primary reports with 6 selected partial-body examinations; density, heterogeneous controls and incomplete access set the confidence, not correctness.", "rests_on_non_peer_reviewed_work": false, "rationale": "Γ follows the preregistered weakest-link bundle (Γ,Ε,Γ,Γ); primary-SC3 and scope-matched sensitivities also return Γ. Model-specific causal contribution earns Ε, while primary sporadic neuronal initiation and clinically proven correction remain unestablished. Functional tissue resistance, acute memory effects, peripheral prevention and FDG changes are kept distinct. Positive models and valid human causal equivalents are assessed together, without automatically re-capping their weaker observational members." }, "role_of_mechanism": { "classification": "downstream consequence", "derivation_step_matched": 1, "derivation": "For the nominal initiating defect, first-match step1 is supported: imposed amyloid/tau disturbance can produce signalling resistance, and disease-model pathology can persist or improve when IGF signalling is blocked. This direction does not exclude reinforcing feedback or permissive insulin support in particular systems; it does not establish a sole native human sequence or a rate-limiting primary driver.", "tournament_used_as_tiebreaker": false, "note": "Derived from causal direction, not tournament rank." }, "extended_scoring_MSD": { "momentum": { "value": "Mechanistic only", "artifact": "The named programmes in this corpus — EVOKE and EVOKE+, the ELAD liraglutide trial and the intranasal insulin/empagliflozin factorial study, together with adult neuronal IGF1R, PTP1B and GLP1 perturbation work — are completed and published rather than running. No presently recruiting study addressing the SC3 boundary check, serial prelesion measurement of human neuronal insulin responsiveness with a selective neuronal instrument, is identified.", "justification": "The named programmes in this corpus — EVOKE and EVOKE+, the ELAD liraglutide trial and the intranasal insulin/empagliflozin factorial study, together with adult neuronal IGF1R, PTP1B and GLP1 perturbation work — are completed and published rather than running. No presently recruiting study addressing the SC3 boundary check, serial prelesion measurement of human neuronal insulin responsiveness with a selective neuronal instrument, is identified." }, "stability": { "value": "Stable", "trigger": "No named pending result is asserted to be likely to move the registered score imminently.", "justification": "No named pending result is asserted to be likely to move the registered score imminently." }, "divergence": { "implied_level": null, "implied_level_basis": "No single field-implied level is defensible from conflicting framings.", "assessed_level": "Γ", "gap_in_rungs": null, "value": "Contested", "justification": "No manufactured field consensus or arithmetic gap." }, "calibration_note": "M/S/D never modify HSEF level or confidence." }, "change_record": { "applies": false, "prior_level": "Ranking categorical verdict visible; no prior letter used as a target", "prior_confidence": null, "prior_source": null, "derived_before_consulting_prior": false, "new_level": "Γ", "direction": "newly assigned", "what_moved_it": "Fresh primary evidence appraisal; not blinded.", "divergence_from_other_reviewers": null }, "proposed_decisive_experiments": [ { "name": "Registered boundary experiment", "experiment": "Predefine an amyloid/tau-negative sporadic-risk cohort with validated live neuron-specific insulin-response measurements; triangulate a selective neuronal exposure instrument and an early CNS-delivered intervention that corrects that response, with matched adult conditional model loss/rescue and repeated pathology/function follow-up.", "readout": "Incident biomarker-confirmed AD and durable cognitive/daily-function trajectory with temporal neuronal mediator correction", "critical_control": "Peripheral glycemia, vascular perfusion, intake/weight, IGF branch, glial engagement, validated delivery device, inactive exposure and prespecified multiplicity", "supporting_result": "Resistance precedes lesions and selective correction prevents conversion through measured neuronal mediation, independently replicated", "falsifying_result": "Resistance follows lesions or selective correction changes signalling without pathology/functional benefit, while systemic/vascular effects explain treatment associations" } ], "knowledge_gaps": [ { "name": "Gap 1", "statement": "Validated live neuron-specific insulin-response assay with orthogonal EV provenance controls.", "relevance": "Limits mechanism identification or scope." }, { "name": "Gap 2", "statement": "Prospective ordering before amyloid/tau rather than before clinical diagnosis.", "relevance": "Limits mechanism identification or scope." }, { "name": "Gap 3", "statement": "Adult neuronal IR-specific loss/rescue separated from IGF, glial and developmental effects.", "relevance": "Limits mechanism identification or scope." }, { "name": "Gap 4", "statement": "Human CNS delivery and receptor/pathway engagement linked to durable benefit in the same participants.", "relevance": "Limits mechanism identification or scope." }, { "name": "Gap 5", "statement": "Prevention in diabetes separated from disease modification in amyloid-confirmed AD and from symptomatic memory effects.", "relevance": "Limits mechanism identification or scope." }, { "name": "Gap 6", "statement": "Independent replication with diet/weight/vascular controls, shared cohorts and outcome multiplicity explicitly accounted for.", "relevance": "Limits mechanism identification or scope." } ], "review_metadata": { "review_date": "2026-10-05", "reviewer": "Codex", "evidence_base_note": "68 primary reports; literature cutoff 2026-10-05; source examination UTC date 2026-10-06; bounded critical review, not exhaustive systematic review.", "literature_tools_available": true, "literature_tools_note": "Life Sciences Literature PubMed/Europe PMC; signed-in Consensus browser discovery and attempted indexed full-text extraction. Successful passages and failures are reconciled with original sections where available; see case reconciliation. Zero Consensus API calls.", "skill_version": "5.3", "validator_run": "exact archived v5.3 validator 2.3; see validator.txt", "validator_warnings_addressed": "Phenomenon entry was restated as the preregistered causal claim. No real phenomenon is labelled refuted; warning is explicitly justified.", "consensus_consistency_audit": "2026-10-09; supplementary provenance/source reconciliation; original grading retained; prior grades visible." }, "is_calibration_entry": { "value": false, "entry_role": "not_calibration", "blind_graded": null, "completed_blinded_calibration": false, "expected_band_sealed_at": "", "target_sha256": "", "target_authorship": "not applicable", "target_author_saw_review": null, "future_run_status": "not prepared", "unblinded_reason": "Ranking categorical verdict and index guidance were visible. No completed blinded calibration claimed." }, "upper_ladder_check": { "final_level_below_zeta": true, "equivalents_considered": [ { "kind": "mendelian_randomization", "available": false, "why_not_sufficient": "Peripheral insulin-sensitivity/T2D MR, multiple insulin/PPAR/GLP1 clinical drug classes and ancillary randomized dementia prevention were examined as legitimate upper-ladder candidates. MR exposures are not neuronal resistance and drugs have divergent/null clinical effects without linked neuronal mediator correction. Dose/genotype/device effects are not concordant independent replications; no unethical neuronal knock-out trial is required." }, { "kind": "natural_experiment", "available": false, "why_not_sufficient": "Peripheral insulin-sensitivity/T2D MR, multiple insulin/PPAR/GLP1 clinical drug classes and ancillary randomized dementia prevention were examined as legitimate upper-ladder candidates. MR exposures are not neuronal resistance and drugs have divergent/null clinical effects without linked neuronal mediator correction. Dose/genotype/device effects are not concordant independent replications; no unethical neuronal knock-out trial is required." }, { "kind": "dose_response_across_populations", "available": false, "why_not_sufficient": "Peripheral insulin-sensitivity/T2D MR, multiple insulin/PPAR/GLP1 clinical drug classes and ancillary randomized dementia prevention were examined as legitimate upper-ladder candidates. MR exposures are not neuronal resistance and drugs have divergent/null clinical effects without linked neuronal mediator correction. Dose/genotype/device effects are not concordant independent replications; no unethical neuronal knock-out trial is required." }, { "kind": "withdrawal_rechallenge", "available": false, "why_not_sufficient": "Peripheral insulin-sensitivity/T2D MR, multiple insulin/PPAR/GLP1 clinical drug classes and ancillary randomized dementia prevention were examined as legitimate upper-ladder candidates. MR exposures are not neuronal resistance and drugs have divergent/null clinical effects without linked neuronal mediator correction. Dose/genotype/device effects are not concordant independent replications; no unethical neuronal knock-out trial is required." }, { "kind": "therapeutic_perturbation_hard_endpoint", "available": false, "why_not_sufficient": "Peripheral insulin-sensitivity/T2D MR, multiple insulin/PPAR/GLP1 clinical drug classes and ancillary randomized dementia prevention were examined as legitimate upper-ladder candidates. MR exposures are not neuronal resistance and drugs have divergent/null clinical effects without linked neuronal mediator correction. Dose/genotype/device effects are not concordant independent replications; no unethical neuronal knock-out trial is required." } ], "convergence_present": true, "cap_reapplied_to_convergent_set": false }, "provenance_header": { "sources_total": 68, "claims_total": 73, "claims_verified": 73, "claims_unverified": 0, "claims_contradicted": 0, "tier_a_sources": 68, "generated_by": "Codex; HSEF v5.3", "gate_passed": true }, "claims": [ { "id": "C1", "text": "AD postmortem brains show lower insulin/IGF pathway expression and altered survival-signalling markers, motivating the type3-diabetes framing. Terminal expression and cell-composition changes do not establish an initiating neuronal endocrine defect or temporal direction.", "carries_number": true, "load_bearing_for": [ "SC1", "SC3" ], "source_ns": [ 1 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C2", "text": "AD hippocampal tissue without diabetes responds less to insulin and IGF challenge; IRS1 serine measures associate with cognition and pathology. Original Methods validate low-PMI tissue and insulin dose responses, but peripheral IR data were unavailable. Original Results find no basal glucose-uptake response to insulin in either group, with glutamate as a positive control. Functional postmortem resistance does not order it before amyloid/tau or establish trajectory benefit.", "carries_number": true, "load_bearing_for": [ "SC1", "SC3" ], "source_ns": [ 2 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. Selected body sections: Results:ex-vivo validation and glucose uptake; Methods:Subjects, tissue preparation, insulin stimulation. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C3", "text": "In 150 matched ROS brains, IRS1 measures and ex-vivo response were not associated with global AD pathology; higher AKT phosphorylation was associated with pathology and lower cognition. Different region, phosphorylation site and assay prevent a simple exact replication claim; AKT integrates other growth-factor signals and tissue was obtained after disease.", "carries_number": true, "load_bearing_for": [ "SC1", "SC3" ], "source_ns": [ 3 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C4", "text": "In the same 150 ROS individuals, higher terminal AKT phosphorylation tracked faster prior cognitive decline; IRS1 signals were largely null. Longitudinal cognition with a terminal pathway assay is not longitudinal neuronal insulin measurement; this is shared-cohort follow-up rather than independent replication.", "carries_number": true, "load_bearing_for": [ "SC1", "SC3" ], "source_ns": [ 4 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C5", "text": "IRS1 serine phosphorylation occurs in AD and other tauopathies; tau transgenics and high-fat diet link it with abnormal tau. Disease specificity and direction are unresolved; abnormal tau can precede the marker and diet affects several metabolic routes.", "carries_number": true, "load_bearing_for": [ "SC1", "SC3" ], "source_ns": [ 5 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C6", "text": "BLSA autopsies link higher tissue glucose, lower glycolytic flux and GLUT3 with AD severity; prior plasma glucose relates to tissue glucose. Glucose accumulation and predominantly insulin-independent transport do not diagnose neuronal insulin resistance; preclinical symptoms are not prelesion order.", "carries_number": true, "load_bearing_for": [ "SC1", "SC3" ], "source_ns": [ 6 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C7", "text": "Peripheral HOMA2 associates with lower hippocampal FDG metabolism and total grey matter in 130 nondiabetic AD participants. HOMA2 measures peripheral resistance, not neuronal response; cross-sectional FDG and volume do not identify initiation or causal mediation.", "carries_number": true, "load_bearing_for": [ "SC1", "SC3" ], "source_ns": [ 7 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C8", "text": "Immunocaptured putative neural exosome IRS1 measures differ in AD, diabetes and FTD; 22 future AD cases show differences 1-10 years before diagnosis. Preclinical clinical timing does not precede amyloid/tau necessarily. Small selected case-control series, classifier validation and disputed L1CAM enrichment constrain neuronal provenance and prediction generalization.", "carries_number": true, "load_bearing_for": [ "SC1", "SC3" ], "source_ns": [ 8 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C9", "text": "L1CAM-enriched vesicle insulin-signalling composite associates with less WMH and greater temporal volume in 88 nondemented ARIC-PET participants. Cross-sectional association, amyloid-dependent attenuation and uncertain neuronal vesicle isolation do not establish causal neuronal signalling or prelesion initiation.", "carries_number": true, "load_bearing_for": [ "SC1", "SC3" ], "source_ns": [ 9 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C10", "text": "Orthogonal biofluid fractionation and single-molecule assays find L1CAM largely outside extracellular vesicles, challenging common neuronal immunocapture assumptions. This validates an assay limitation rather than absence of all neural EVs or falsity of every IRS1 signal; protocol and antibody-specific follow-up is necessary.", "carries_number": true, "load_bearing_for": [ "SC1", "SC3" ], "source_ns": [ 10 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C11", "text": "Single-EV methods find L1CAM epitopes co-expressed with neuronal proteins and enrichment relative to L1CAM-negative EVs. Original Results include detergent, isotype, background, tetraspanin and hepatocyte-marker controls; 5G3 immunocapture enriches a subset co-carrying neuronal markers. Most soluble L1CAM remains outside EVs. This supports specific procedures rather than universal neuronal purity or live-cell insulin response.", "carries_number": true, "load_bearing_for": [ "SC1", "SC3" ], "source_ns": [ 11 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:RESULTS:paragraph6, 1:RESULTS:paragraph9, 1:RESULTS:paragraph12, 1:RESULTS:paragraph15, 1:RESULTS:paragraph18. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C12", "text": "Across plasma, CSF and induced-neuron media, generic EVs and neuronal cargo are recovered but L1CAM predominantly remains free and is not enriched by immunocapture. Original Methods/Results use the same common 5G3 clone, calnexin-negative capture, EV markers, neuronal versus hematopoietic media and free-protein fractions. CSF proteomics is one pooled experiment. Negative enrichment differs from single-EV positive procedures; neither result measures live neuronal insulin causality.", "carries_number": true, "load_bearing_for": [ "SC1", "SC3" ], "source_ns": [ 12 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Materials and Methods:paragraph3, 1:Materials and Methods:paragraph9, 1:Materials and Methods:paragraph13, 2:Results:paragraph2, 2:Results:paragraph3, 2:Results:paragraph7, 2:Results:paragraph9, 2:Results:paragraph10, 2:Results:paragraph12. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C13", "text": "NIRKO loses insulin-mediated signalling and increases tau phosphorylation while showing no neuronal survival, memory or basal brain glucose deficit. Developmental deletion and compensation may mask adult functions, but marker changes alone are insufficient to generate AD-like functional degeneration in this tested context.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 13 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C14", "text": "Global IRS2 loss reduces developmental neuronal proliferation and older mice accumulate phosphorylated tau pathology. Major developmental growth and peripheral diabetes effects prevent isolation of an adult neuronal initiating mechanism or specificity to sporadic AD.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 14 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C15", "text": "Neural insulin-receptor deletion alters feeding, obesity and reproductive control without altered brain development or neuronal survival. Systemic consequences and developmental timing matter; metabolic regulation by brain IR is not sufficient proof of AD initiation.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 15 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C16", "text": "Adult neuron-specific IGF1R deletion in APP/PS1 mice improves spatial memory and reduces amyloid/inflammation, with neuronal structural changes and higher plasma amyloid. The direction opposes simple restoration of deficient IGF signalling. An adult genetic intervention is credited, but an APP/PS1 disease substrate and cell-size/proteostasis effects do not establish sporadic human primacy.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 16 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C17", "text": "IRS2 or neuronal IGF1R loss reduces amyloid and prevents premature Tg2576 death; neuronal IR loss does not alter lethality. Insulin and IGF branches differ. Developmental manipulation, sex differences and transgenic premature mortality constrain interpretation as natural aging or sporadic AD.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 17 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C18", "text": "Reduced IGF signalling protects AD-model mice against behavioural deficits, inflammation and neuronal loss while promoting dense amyloid aggregates. Protection from reduced signalling challenges a uniformly deficient-signalling model; developmental, aggregation and transgenic-context effects remain.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 18 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C19", "text": "Tau deletion impairs hippocampal insulin response through IRS1/PTEN and changes hypothalamic insulin effects; human tau haplotypes associate with glycemic traits. Provides a tau-to-insulin direction in models, not proof of the sole human ordering; lifelong deletion and peripheral glycemic traits do not reproduce pathological tau loss selectively.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 19 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C20", "text": "Amyloid oligomers activate JNK/TNF, inhibit IRS1 signalling in neurons and primate challenge, while exendin4 restores neuronal transport and improves transgenic-mouse cognition. Original Methods use male APP/PS1 mice and imposed primate oligomers; behavioural treatment starts at nine months. Comparable slight weight loss limits a simple caloric explanation, but GLP1 pleiotropy and no neuronal-IR-specific epistasis remain. Amyloid can induce resistance; rescue does not establish primary sporadic initiation.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 20 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. Selected body sections: Results:Figure8 and exendin4 rescue; Methods:primate infusion, APP/PS1 animals and behavioural tests. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C21", "text": "TNFR1/PKR disruption blocks oligomer-induced translation-signalling changes and memory impairment; insulin support rescues pathway abnormalities. Challenge genetics establish an amyloid-to-inflammatory/IRS1 injury route, not endogenous sporadic neuronal insulin failure as the first lesion.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 21 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C22", "text": "Insulin prevents oligomer-induced surface IR loss, oxidative stress and spine deterioration; kinase inhibition abolishes protection and rosiglitazone potentiates it. Culture rescue does not establish organismal trajectory change or natural initiation. A linked unidentified erratum remains unresolved.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 22 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C23", "text": "Active AKT, GSK3 inhibition and exendin4 prevent or reverse oligomer-induced BDNF transport deficits in wild-type and tau-null neurons. A transport rescue after imposed amyloid is narrower than survival or clinical benefit and is compatible with a reinforcing feedback pathway.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 23 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C24", "text": "Oligomers transiently inhibit AMPK/ATP and remove dendritic glucose transporters; NMDA-related intervention and insulin protect these measures. Acute metabolic responses after imposed amyloid are not proof of primary neuronal insulin resistance or sustained organismal disease modification.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 24 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C25", "text": "Reducing fly insulin signalling suppresses expressed-Aβ toxicity; Aβ elevates brain insulin signalling while peripheral signalling falls. A different species adds direction discrimination but is an imposed peptide system; IDE competition and branch/tissue effects oppose a simple low-signalling master mechanism.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 25 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C26", "text": "IR beta-subunit haploinsufficiency impairs late LTP and recognition memory. A lifelong global dosage change demonstrates a memory contribution in this background, not adult neuron-specific AD initiation or neurodegenerative trajectory.", "carries_number": false, "load_bearing_for": [ "SC2" ], "source_ns": [ 26 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C27", "text": "Neuronal PTP1B ablation and systemic trodusquemine prevent neuron loss and spatial memory deficits in hAPP-J20 mice; neuronal ablation preserves benefit without reducing inflammation. An endogenous signalling regulator is tested within an amyloid transgenic substrate, but PTP1B affects multiple receptors; restoration of insulin signalling specifically is not isolated by the abstract.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 27 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C28", "text": "Adult neuronal IGF1R suppression protects against oligomer-induced memory and inflammatory injury; related APP/PS1 transcriptional signatures converge. Shares the adult IGF-deletion programme with PMID26290229. Transcriptomic similarity is a lead, not independent causal proof; loss of the IGF branch again protects rather than harms.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 28 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C29", "text": "Central, but not systemic, oligomer infusion induces peripheral glucose intolerance; TNFR1 loss and central inflammatory/ER-stress inhibition prevent it. Demonstrates brain injury can drive peripheral metabolic change. Imposed exposure and transgenics do not establish native human direction or exclude reciprocal metabolic risk.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 29 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C30", "text": "Astrocyte IR deletion alters ATP exocytosis and dopamine-related behaviour; central ATP analog rescues depressive-like behaviour. A cell-type-specific glial route is functional but is neither neuronal insulin resistance nor AD initiation, and the behavioural endpoint is not AD cognitive trajectory.", "carries_number": false, "load_bearing_for": [ "SC2" ], "source_ns": [ 30 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C31", "text": "Inducible astrocyte IGFR loss impairs working memory, mitochondrial function and glucose/amyloid uptake. Astrocytic support differs from adult neuronal IGFR loss; single-context functional benefit and cultured mitochondrial changes do not establish a uniform neuronal mechanism.", "carries_number": false, "load_bearing_for": [ "SC2" ], "source_ns": [ 31 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C32", "text": "Inducible microglial IR loss impairs amyloid uptake and increases plaque/inflammation in 5xFAD, with mood/social changes. Microglial rather than neuronal perturbation, an imposed familial substrate and no demonstrated AD cognitive rescue constrain the registered neuronal claim. Updated preprint is not counted again.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 32 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C33", "text": "Prolonged high-fat diet worsens cognition and soluble amyloid in APP/PS1 mice while central and peripheral transporter responses differ. Diet begins at one month and changes lipids/inflammation/intake; broad developmental and systemic exposure cannot isolate adult neuronal insulin resistance.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 33 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C34", "text": "Intracerebroventricular STZ worsens Tg2576 spatial cognition, mortality and amyloid/tau measures. STZ is a toxic imposed trigger with effects beyond insulin signalling. Combining it with APP overexpression is not selective sufficiency for sporadic AD.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 34 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C35", "text": "Induced diabetes increases subicular amyloid plaques in middle-aged 3xTg mice but does not worsen learning/memory or AT8 burden. A functional negative comparator prevents biomarker-only changes earning trajectory credit; dose, timing and model baseline bound the null result.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 35 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C36", "text": "In 118 medication-treated ACT autopsies, conventional AD neuropathology is not associated with drug class; some adjusted quantitative amyloid measures are lower. Small descriptive analysis and indication/severity confounding cannot establish therapeutic neuronal insulin mediation or clinical disease modification.", "carries_number": true, "load_bearing_for": [ "SC1", "SC4" ], "source_ns": [ 36 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C37", "text": "In the same 150 ROS brains, stimulated AKT and cytoplasmic IRS1 measures associate with infarcts, with a separate amyloid-angiopathy association. Shared cohort adds vascular specificity rather than independent replication; infarction can cause cognition/AD-like symptoms without proving neuronal insulin primacy.", "carries_number": true, "load_bearing_for": [ "SC1", "SC3" ], "source_ns": [ 37 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C38", "text": "Prospective Rotterdam data link diabetes to incident clinically diagnosed dementia and AD over mean 2.1 years. Peripheral diabetes, clinical diagnosis and short prediagnosis follow-up do not distinguish vascular contribution, preclinical reverse causation or neuronal initiating resistance; insulin treatment marks severity.", "carries_number": true, "load_bearing_for": [ "SC3" ], "source_ns": [ 38 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C39", "text": "Lower serum IGF1 predicts higher AD dementia incidence in Framingham and higher IGF1 associates with greater brain volume. Serum hormone is not neuronal receptor responsiveness; cohort confounding and clinically dementia-free enrollment do not establish preamyloid initiation.", "carries_number": true, "load_bearing_for": [ "SC3" ], "source_ns": [ 39 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C40", "text": "Genetically higher peripheral insulin sensitivity associates with lower AD risk in two outcome datasets, with attenuation after adjusting for T2D. MR is credited as an upper-ladder equivalent on its exposure, but peripheral sensitivity is not a selective neuronal signalling instrument and multivariable attenuation does not by itself prove mediation.", "carries_number": true, "load_bearing_for": [ "SC3" ], "source_ns": [ 40 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C41", "text": "Large T2D genetic instruments do not show an AD effect in the primary or FinnGen analysis. Null peripheral-liability estimates do not refute neuronal insulin resistance; largely overlapping FinnGen exposure/outcome samples and disease ascertainment matter.", "carries_number": true, "load_bearing_for": [ "SC3" ], "source_ns": [ 41 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C42", "text": "Overall T2D polygenic liability is null for AD, while a mechanism-specific insulin-sensitivity score predicts AD risk in IGAP. The corresponding HRS cognition association is nonsignificant. Instrument subclass, pleiotropy and shared GWAS require caution, and peripheral sensitivity is not neuron-specific primacy.", "carries_number": true, "load_bearing_for": [ "SC3" ], "source_ns": [ 42 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C43", "text": "Semaglutide improves short-term cognition and glucose/pathology measures in 3xTg mice; SIRT1 inhibition blocks cultured metabolic effects. Single-background, short-horizon functional benefit and cell-level epistasis do not establish human disease modification or that insulin failure was upstream of transgenic amyloid/tau.", "carries_number": true, "load_bearing_for": [ "SC2", "SC4" ], "source_ns": [ 43 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C44", "text": "Seven-day intranasal insulin in 3xTg mice restores signalling/synaptic proteins and lowers Aβ40 and microglial activation. No functional benefit is measured here, and tau phosphorylation, glucose transporters and O-GlcNAcylation are unchanged; biomarker effects do not cross the trajectory boundary.", "carries_number": true, "load_bearing_for": [ "SC2", "SC4" ], "source_ns": [ 44 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C45", "text": "In 38 healthy participants, eight-week intranasal insulin improves delayed recall without plasma insulin/glucose change. Normal memory modulation is a credible central-function effect but does not demonstrate AD disease modification or receptor-specific neuronal engagement.", "carries_number": true, "load_bearing_for": [ "SC2", "SC4" ], "source_ns": [ 45 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C46", "text": "With the tested Aero Pump lispro regimen, human CSF drug is below quantification despite detection in beagle CSF. Direct delivery limitation is regimen/species-specific; CSF absence does not universally exclude local brain delivery, but animal exposure cannot validate human delivery.", "carries_number": false, "load_bearing_for": [ "SC4" ], "source_ns": [ 46 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C47", "text": "Intranasal radiolabelled insulin with an Aptar device reaches multiple brain regions in 16 older CN/MCI participants. Radiotracer distribution validates this device/exposure route, not therapeutic receptor phosphorylation, sustained bioactive concentration or clinical efficacy in other devices.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 47 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C48", "text": "Twenty-one-day randomized insulin pilot improves delayed recall, attention and caregiver function in 25 early AD/MCI participants without changed fasting insulin/glucose. Small short-term clinical changes can be symptomatic; multiple outcomes, diagnostic heterogeneity and an unresolved linked erratum limit trajectory inference.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 48 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C49", "text": "Four-month 104-person pilot finds improved delayed memory at 20 IU and preserved caregiver function at both doses, with exploratory FDG and CSF correlations. Small endpoint subsets, subgroup effects and no group CSF biomarker shift do not establish durable disease modification or selective neuronal insulin correction.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 49 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C50", "text": "In a 60-person 21-day detemir trial, high-dose memory effects differ by APOE, with improvement in carriers and worsening in noncarriers; daily function is null. Short-term, genotype-dependent effects require replication; baseline peripheral resistance is not brain target engagement. Linked erratum PMID25869922 is not a primary study.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 50 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C51", "text": "In a 36-person four-month trial, regular insulin improves memory while detemir and daily function are null; MRI and CSF-ratio signals accompany regular insulin. Small groups and outcomes constrain durable inference; a formulation-specific symptomatic response does not identify primary aetiology.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 51 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C52", "text": "Thirty-five-person glulisine trial shows no cognitive, functional or mood benefit at three/six months. Enrollment/duration and age imbalance limit precision; no selective neuronal engagement result is provided in the abstract, so this regimen's failure is bounded.", "carries_number": false, "load_bearing_for": [ "SC4" ], "source_ns": [ 52 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C53", "text": "SNIFF randomizes 289; the prespecified device2 cohort of 240 has no 12-month ADAS-cog benefit or secondary clinical/CSF benefit, with difference 0.0258 and P=.98. Original Methods define device2 as primary before lock with serial clinical gatekeeping. Device1 has nominal six-month but nonsignificant twelve-month cognition and greater entorhinal volume loss; device2 has small greater hippocampal loss. Primary CSF insulin is unchanged, leaving delivery/engagement uncertain rather than proving no transient neuronal effect.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 53 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. Selected body sections: Methods:Participants, Statistical Analysis; Results:CSF, Secondary Analyses. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C54", "text": "In SNIFF's 49-person device1 subgroup, insulin reduces deep/frontal WMH progression associated with clinical and CSF measures. This is a secondary analysis of the same selected device cohort, not independent trial replication or direct neuronal signalling engagement.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 54 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C55", "text": "SNIFF's cohort showing benefit has treatment-related CSF IL6, interferon-gamma and eotaxin changes with exploratory clinical/imaging associations. Selected shared cohort, multiple marker tests and inflammatory rather than neuron-specific engagement limit mechanistic inference; the large primary cohort remains null.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 55 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C56", "text": "Thirty-eight-person six-month liraglutide trial reports preserved FDG metabolism but no between-group amyloid effect or cognitive change. Underpowered cognition and predominantly biomarker effects do not establish clinical trajectory modification; between-arm evidence must be distinguished from within-arm decline.", "carries_number": false, "load_bearing_for": [ "SC4" ], "source_ns": [ 56 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C57", "text": "Reanalysis of the same 38-person liraglutide trial estimates increased blood-brain glucose transport capacity relative to placebo. Model-derived BBB transfer is a distinct downstream endpoint, not direct neuronal IR correction or a second independent clinical trial.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 57 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C58", "text": "ELAD randomizes 204 and finds no primary FDG difference or CDR/ADL benefit; ADAS-Exec has an unadjusted secondary signal. Original Methods use154 complete SUV scans and101 spectral sensitivity scans without outcome imputation; no CSF was collected and planned tau/TSPO PET was not done. Exploratory MRI, weight loss and limited brain-penetration arguments do not directly verify neuronal insulin engagement.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 58 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Results:paragraph0, 1:Results:paragraph15, 1:Results:paragraph17, 1:Results:paragraph19, 1:Results:paragraph20, 1:Results:paragraph22, 1:Results:paragraph24, 3:Methods:paragraph1, 3:Methods:paragraph3, 3:Methods:paragraph5, 3:Methods:paragraph6, 3:Methods:paragraph10, 3:Methods:paragraph12, 3:Methods:paragraph63, 3:Methods:paragraph65, 3:Methods:paragraph66. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C59", "text": "Early-terminated exenatide pilot has 18 completers and no clinical, cognitive, MRI or main fluid response; EV Aβ42 alone falls. Severe power limitation and disputed neural EV provenance constrain interpretation; isolated EV biomarker improvement is not clinical disease modification.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 59 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C60", "text": "Thirty-two MCI participants randomized to weekly exenatide or no treatment show no ADAS-Cog benefit; weight/glucose fall and a female-worsening interaction is reported. Small open comparator and subgroup multiplicity limit the interaction; systemic engagement does not demonstrate correction of brain neuronal insulin resistance.", "carries_number": false, "load_bearing_for": [ "SC4" ], "source_ns": [ 60 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C61", "text": "EVOKE and EVOKE+ randomize3808 amyloid-confirmed early AD participants; semaglutide does not improve 104-week CDR-SB in either trial, with differences -.08 and +.10. Primary abstract/status was examined; original numerical body was unavailable. Strong regimen-level clinical negatives do not demonstrate selective restoration of deficient neuronal signalling or refute every earlier metabolic-risk contribution.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 61 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C62", "text": "Matched US diabetes EHR emulations associate semaglutide with lower first AD diagnosis than seven active medication comparators. Target-trial emulation remains nonrandomized; indication, residual severity/adherence/ascertainment and clinically unrecognized preexisting pathology persist. Prevention in diabetes is a different estimand from EVOKE symptomatic AD.", "carries_number": false, "load_bearing_for": [ "SC3", "SC4" ], "source_ns": [ 62 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C63", "text": "Pooled diabetes cardiovascular trials and Danish prescriptions both show lower recorded dementia with GLP1RA exposure; randomized estimate HR=.47. Random allocation deserves causal credit for this ancillary dementia outcome, not dismissal as observational. Endpoint capture, mixed source classes and systemic/vascular effects do not identify neuronal insulin mediation or established AD progression.", "carries_number": true, "load_bearing_for": [ "SC3", "SC4" ], "source_ns": [ 63 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C64", "text": "693-person rosiglitazone monotherapy phase3 trial fails prespecified cognition/global endpoints overall and in prospectively stratified APOE4-negative participants. Failure of this dose/PPAR regimen is not proof of an engaged neuronal IR defect's irrelevance; the earlier genotype rescue prediction did not replicate.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 64 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C65", "text": "Two rosiglitazone adjunct phase3 trials of 1496 and 1485 participants fail 48-week cognition/global endpoints with no APOE interaction. Two trials in one report strengthen clinical nonreplication, while PPAR pleiotropy and uncertain brain exposure prevent a universal insulin-mechanism exclusion.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 65 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C66", "text": "TOMMORROW enrolls 3494 cognitively healthy participants; low-dose pioglitazone does not delay MCI and the trial stops for futility. 0.8 mg regimen, incomplete event accrual and genetic-risk selection constrain prevention inference; the risk algorithm also misses its prespecified significance threshold and neuronal engagement is not established.", "carries_number": true, "load_bearing_for": [ "SC3", "SC4" ], "source_ns": [ 66 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C67", "text": "In 80 overweight/obese aMCI adults without treated diabetes, metformin improves one adjusted recall outcome but not ADAS-cog or other endpoints. Baseline imbalance, low maximal-dose tolerability, multiple endpoints and no neuron-specific target engagement limit disease-modification inference.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 67 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C68", "text": "Four-week factorial insulin/empagliflozin trial meets safety aims and reports promising secondary cognition, perfusion and fluid-marker changes. Primary outcome is adverse events; short duration and secondary outcomes require larger longer confirmation. Empagliflozin vascular/systemic effects and fluid changes do not identify neuronal initiating resistance.", "carries_number": false, "load_bearing_for": [ "SC4" ], "source_ns": [ 68 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "CSC1", "text": "Functional postmortem challenge supports insulin/IGF resistance in selected AD hippocampal samples without diabetes, beyond static marker abundance. Other region/site assays are null or show higher downstream AKT activity. Γ records support for this finding within the causal review; it does not deny the observed functional resistance. No disease-trajectory crossing is inferred from tissue responsiveness alone.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 36, 37 ], "verification": "verified", "verified_against": "Synthesis of examined primary result/limit cards; framework level is adjudication.", "verified_on": "2026-10-06", "note": "" }, { "id": "CSC2", "text": "Loss, rescue and pathway support affect synaptic or cognitive function in defined models, reaching constrained causal contribution. Adult glial deletions demonstrate cell-type differences and neuronal PTP1B/GLP1 manipulations protect disease-model function. The IR and IGF branches cannot be merged: neuronal IGF attenuation can instead be protective, and selective adult neuronal IR mediation remains incompletely isolated.", "carries_number": false, "load_bearing_for": [ "SC2" ], "source_ns": [ 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 43, 44, 45 ], "verification": "verified", "verified_against": "Synthesis of examined primary result/limit cards; framework level is adjudication.", "verified_on": "2026-10-06", "note": "" }, { "id": "CSC3", "text": "Primary upstream failure remains a mechanistic possibility supported by imposed metabolic injury and antecedent peripheral/putative EV clues, but no selective neuronal instrument or serial preamyloid/tau functional assay establishes sporadic human order. Models demonstrate the opposite direction as well. Γ is an unmet positive primacy burden, not a blanket observational cap imposed on the entire convergent set.", "carries_number": false, "load_bearing_for": [ "SC3" ], "source_ns": [ 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 27, 28, 29, 32, 33, 34, 35, 37, 38, 39, 40, 41, 42, 62, 63, 66 ], "verification": "verified", "verified_against": "Synthesis of examined primary result/limit cards; framework level is adjudication.", "verified_on": "2026-10-06", "note": "" }, { "id": "CSC4", "text": "Small insulin/metformin and recent short factorial trials show scoped clinical signals, but larger insulin, rosiglitazone, pioglitazone and GLP1 trials do not establish reproducible disease modification. SNIFF delivery uncertainty and pleiotropic/systemic engagement prevent interpreting failed regimens as a universal negative neuronal mechanism test. ELAD secondary cognition is unadjusted and EVOKE clinical outcomes are null.", "carries_number": false, "load_bearing_for": [ "SC4" ], "source_ns": [ 36, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68 ], "verification": "verified", "verified_against": "Synthesis of examined primary result/limit cards; framework level is adjudication.", "verified_on": "2026-10-06", "note": "" }, { "id": "CH", "text": "Brain insulin signalling is altered in some AD assays and can modify injury in models, but a primary neuronal insulin/IGF defect initiating sporadic AD and proven clinical correction remain unestablished.", "carries_number": false, "load_bearing_for": [ "SC3" ], "source_ns": [ 2, 13, 16, 53, 58, 61 ], "verification": "verified", "verified_against": "Bounded synthesis of examined sources; score is adjudication.", "verified_on": "2026-10-06", "note": "" } ], "citation_ledger": [ { "n": 1, "citation": "Steen E, Terry BM, Rivera EJ et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes? Journal of Alzheimer's disease : JAD. 2005.", "tier": "A", "kind": "primary", "pmid": "15750215", "doi": "10.3233/jad-2005-7107", "url": "https://pubmed.ncbi.nlm.nih.gov/15750215/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID15750215", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C1", "CSC1", "CSC3" ] }, { "n": 2, "citation": "Talbot K, Wang HY, Kazi H et al. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. The Journal of clinical investigation. 2012.", "tier": "A", "kind": "primary", "pmid": "22476197", "doi": "10.1172/JCI59903", "url": "https://pubmed.ncbi.nlm.nih.gov/22476197/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID22476197", "access_depth": "full_text_partial", "access_note": "Complete primary abstract and linked-status metadata examined. Selected body sections: Results:ex-vivo validation and glucose uptake; Methods:Subjects, tissue preparation, insulin stimulation. No complete-paper or supplement audit claimed.", "carries_claims": [ "C2", "CSC1", "CSC3", "CH" ] }, { "n": 3, "citation": "Arvanitakis Z, Wang HY, Capuano AW et al. Brain Insulin Signaling, Alzheimer Disease Pathology, and Cognitive Function. Annals of neurology. 2020.", "tier": "A", "kind": "primary", "pmid": "32557841", "doi": "10.1002/ana.25826", "url": "https://pubmed.ncbi.nlm.nih.gov/32557841/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "ROS-150-matched-brains", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C3", "CSC1", "CSC3" ] }, { "n": 4, "citation": "Tong H, Capuano AW, Carmichael OT et al. Brain Insulin Signaling is Associated with Late-Life Cognitive Decline. Aging and disease. 2024.", "tier": "A", "kind": "primary", "pmid": "38029396", "doi": "10.14336/AD.2023.1117", "url": "https://pubmed.ncbi.nlm.nih.gov/38029396/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "ROS-150-matched-brains", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C4", "CSC1", "CSC3" ] }, { "n": 5, "citation": "Yarchoan M, Toledo JB, Lee EB et al. Abnormal serine phosphorylation of insulin receptor substrate 1 is associated with tau pathology in Alzheimer's disease and tauopathies. Acta neuropathologica. 2014.", "tier": "A", "kind": "primary", "pmid": "25107476", "doi": "10.1007/s00401-014-1328-5", "url": "https://pubmed.ncbi.nlm.nih.gov/25107476/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID25107476", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C5", "CSC1", "CSC3" ] }, { "n": 6, "citation": "An Y, Varma VR, Varma S et al. Evidence for brain glucose dysregulation in Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2018.", "tier": "A", "kind": "primary", "pmid": "29055815", "doi": "10.1016/j.jalz.2017.09.011", "url": "https://pubmed.ncbi.nlm.nih.gov/29055815/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID29055815", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C6", "CSC1", "CSC3" ] }, { "n": 7, "citation": "Femminella GD, Livingston NR, Raza S et al. Does insulin resistance influence neurodegeneration in non-diabetic Alzheimer's subjects? Alzheimer's research & therapy. 2021.", "tier": "A", "kind": "primary", "pmid": "33597002", "doi": "10.1186/s13195-021-00784-w", "url": "https://pubmed.ncbi.nlm.nih.gov/33597002/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID33597002", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C7", "CSC1", "CSC3" ] }, { "n": 8, "citation": "Kapogiannis D, Boxer A, Schwartz JB et al. Dysfunctionally phosphorylated type 1 insulin receptor substrate in neural-derived blood exosomes of preclinical Alzheimer's disease. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2015.", "tier": "A", "kind": "primary", "pmid": "25342129", "doi": "10.1096/fj.14-262048", "url": "https://pubmed.ncbi.nlm.nih.gov/25342129/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID25342129", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C8", "CSC1", "CSC3" ] }, { "n": 9, "citation": "Walker KA, Chawla S, Nogueras-Ortiz C et al. Neuronal insulin signaling and brain structure in nondemented older adults: the Atherosclerosis Risk in Communities Study. Neurobiology of aging. 2021.", "tier": "A", "kind": "primary", "pmid": "33160263", "doi": "10.1016/j.neurobiolaging.2020.09.022", "url": "https://pubmed.ncbi.nlm.nih.gov/33160263/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID33160263", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C9", "CSC1", "CSC3" ] }, { "n": 10, "citation": "Norman M, Ter-Ovanesyan D, Trieu W et al. L1CAM is not associated with extracellular vesicles in human cerebrospinal fluid or plasma. Nature methods. 2021.", "tier": "A", "kind": "primary", "pmid": "34092791", "doi": "10.1038/s41592-021-01174-8", "url": "https://pubmed.ncbi.nlm.nih.gov/34092791/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID34092791", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C10", "CSC1", "CSC3" ] }, { "n": 11, "citation": "Nogueras-Ortiz CJ, Eren E, Yao P et al. Single-extracellular vesicle (EV) analyses validate the use of L1 Cell Adhesion Molecule (L1CAM) as a reliable biomarker of neuron-derived EVs. Journal of extracellular vesicles. 2024.", "tier": "A", "kind": "primary", "pmid": "38868956", "doi": "10.1002/jev2.12459", "url": "https://pubmed.ncbi.nlm.nih.gov/38868956/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID38868956", "access_depth": "full_text_partial", "access_note": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:RESULTS:paragraph6, 1:RESULTS:paragraph9, 1:RESULTS:paragraph12, 1:RESULTS:paragraph15, 1:RESULTS:paragraph18. No complete-paper or supplement audit claimed.", "carries_claims": [ "C11", "CSC1", "CSC3" ] }, { "n": 12, "citation": "Kadam V, Wacker M, Oeckl P et al. Most L1CAM Is not Associated with Extracellular Vesicles in Human Biofluids and iPSC-Derived Neurons. Molecular neurobiology. 2025.", "tier": "A", "kind": "primary", "pmid": "40210837", "doi": "10.1007/s12035-025-04909-2", "url": "https://pubmed.ncbi.nlm.nih.gov/40210837/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID40210837", "access_depth": "full_text_partial", "access_note": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Materials and Methods:paragraph3, 1:Materials and Methods:paragraph9, 1:Materials and Methods:paragraph13, 2:Results:paragraph2, 2:Results:paragraph3, 2:Results:paragraph7, 2:Results:paragraph9, 2:Results:paragraph10, 2:Results:paragraph12. No complete-paper or supplement audit claimed.", "carries_claims": [ "C12", "CSC1", "CSC3" ] }, { "n": 13, "citation": "Schubert M, Gautam D, Surjo D et al. Role for neuronal insulin resistance in neurodegenerative diseases. Proceedings of the National Academy of Sciences of the United States of America. 2004.", "tier": "A", "kind": "primary", "pmid": "14981233", "doi": "10.1073/pnas.0308724101", "url": "https://pubmed.ncbi.nlm.nih.gov/14981233/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID14981233", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C13", "CSC2", "CSC3", "CH" ] }, { "n": 14, "citation": "Schubert M, Brazil DP, Burks DJ et al. Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2003.", "tier": "A", "kind": "primary", "pmid": "12904469", "doi": "10.1523/JNEUROSCI.23-18-07084.2003", "url": "https://pubmed.ncbi.nlm.nih.gov/12904469/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID12904469", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C14", "CSC2", "CSC3" ] }, { "n": 15, "citation": "Brüning JC, Gautam D, Burks DJ et al. Role of brain insulin receptor in control of body weight and reproduction. Science (New York, N.Y.). 2000.", "tier": "A", "kind": "primary", "pmid": "11000114", "doi": "10.1126/science.289.5487.2122", "url": "https://pubmed.ncbi.nlm.nih.gov/11000114/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID11000114", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C15", "CSC2", "CSC3" ] }, { "n": 16, "citation": "Gontier G, George C, Chaker Z et al. Blocking IGF Signaling in Adult Neurons Alleviates Alzheimer's Disease Pathology through Amyloid-β Clearance. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2015.", "tier": "A", "kind": "primary", "pmid": "26290229", "doi": "10.1523/JNEUROSCI.0343-15.2015", "url": "https://pubmed.ncbi.nlm.nih.gov/26290229/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "Adult-neuronal-IGF1R-programme", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C16", "CSC2", "CSC3", "CH" ] }, { "n": 17, "citation": "Freude S, Hettich MM, Schumann C et al. Neuronal IGF-1 resistance reduces Abeta accumulation and protects against premature death in a model of Alzheimer's disease. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2009.", "tier": "A", "kind": "primary", "pmid": "19487308", "doi": "10.1096/fj.09-132043", "url": "https://pubmed.ncbi.nlm.nih.gov/19487308/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID19487308", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C17", "CSC2", "CSC3" ] }, { "n": 18, "citation": "Cohen E, Paulsson JF, Blinder P et al. Reduced IGF-1 signaling delays age-associated proteotoxicity in mice. Cell. 2009.", "tier": "A", "kind": "primary", "pmid": "20005808", "doi": "10.1016/j.cell.2009.11.014", "url": "https://pubmed.ncbi.nlm.nih.gov/20005808/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID20005808", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C18", "CSC2", "CSC3" ] }, { "n": 19, "citation": "Marciniak E, Leboucher A, Caron E et al. Tau deletion promotes brain insulin resistance. The Journal of experimental medicine. 2017.", "tier": "A", "kind": "primary", "pmid": "28652303", "doi": "10.1084/jem.20161731", "url": "https://pubmed.ncbi.nlm.nih.gov/28652303/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID28652303", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C19", "CSC2", "CSC3" ] }, { "n": 20, "citation": "Bomfim TR, Forny-Germano L, Sathler LB et al. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers. The Journal of clinical investigation. 2012.", "tier": "A", "kind": "primary", "pmid": "22476196", "doi": "10.1172/JCI57256", "url": "https://pubmed.ncbi.nlm.nih.gov/22476196/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID22476196", "access_depth": "full_text_partial", "access_note": "Complete primary abstract and linked-status metadata examined. Selected body sections: Results:Figure8 and exendin4 rescue; Methods:primate infusion, APP/PS1 animals and behavioural tests. No complete-paper or supplement audit claimed.", "carries_claims": [ "C20", "CSC2", "CSC3" ] }, { "n": 21, "citation": "Lourenco MV, Clarke JR, Frozza RL et al. TNF-α mediates PKR-dependent memory impairment and brain IRS-1 inhibition induced by Alzheimer's β-amyloid oligomers in mice and monkeys. Cell metabolism. 2013.", "tier": "A", "kind": "primary", "pmid": "24315369", "doi": "10.1016/j.cmet.2013.11.002", "url": "https://pubmed.ncbi.nlm.nih.gov/24315369/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID24315369", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C21", "CSC2", "CSC3" ] }, { "n": 22, "citation": "De Felice FG, Vieira MN, Bomfim TR et al. Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proceedings of the National Academy of Sciences of the United States of America. 2009.", "tier": "A", "kind": "primary", "pmid": "19188609", "doi": "10.1073/pnas.0809158106", "url": "https://pubmed.ncbi.nlm.nih.gov/19188609/", "status_flags": [ "ErratumIn: PMID not supplied" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID19188609", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C22", "CSC2", "CSC3" ] }, { "n": 23, "citation": "Takach O, Gill TB, Silverman MA et al. Modulation of insulin signaling rescues BDNF transport defects independent of tau in amyloid-β oligomer-treated hippocampal neurons. Neurobiology of aging. 2015.", "tier": "A", "kind": "primary", "pmid": "25543463", "doi": "10.1016/j.neurobiolaging.2014.11.018", "url": "https://pubmed.ncbi.nlm.nih.gov/25543463/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID25543463", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C23", "CSC2", "CSC3" ] }, { "n": 24, "citation": "Seixas da Silva GS, Melo HM, Lourenco MV et al. Amyloid-β oligomers transiently inhibit AMP-activated kinase and cause metabolic defects in hippocampal neurons. The Journal of biological chemistry. 2017.", "tier": "A", "kind": "primary", "pmid": "28302722", "doi": "10.1074/jbc.M116.753525", "url": "https://pubmed.ncbi.nlm.nih.gov/28302722/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID28302722", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C24", "CSC2", "CSC3" ] }, { "n": 25, "citation": "Huang Y, Wan Z, Wang Z et al. Insulin signaling in Drosophila melanogaster mediates Aβ toxicity. Communications biology. 2019.", "tier": "A", "kind": "primary", "pmid": "30652125", "doi": "10.1038/s42003-018-0253-x", "url": "https://pubmed.ncbi.nlm.nih.gov/30652125/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID30652125", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C25", "CSC2", "CSC3" ] }, { "n": 26, "citation": "Nisticò R, Cavallucci V, Piccinin S et al. Insulin receptor β-subunit haploinsufficiency impairs hippocampal late-phase LTP and recognition memory. Neuromolecular medicine. 2012.", "tier": "A", "kind": "primary", "pmid": "22661254", "doi": "10.1007/s12017-012-8184-z", "url": "https://pubmed.ncbi.nlm.nih.gov/22661254/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID22661254", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C26", "CSC2" ] }, { "n": 27, "citation": "Ricke KM, Cruz SA, Qin Z et al. Neuronal Protein Tyrosine Phosphatase 1B Hastens Amyloid β-Associated Alzheimer's Disease in Mice. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2020.", "tier": "A", "kind": "primary", "pmid": "31915254", "doi": "10.1523/JNEUROSCI.2120-19.2019", "url": "https://pubmed.ncbi.nlm.nih.gov/31915254/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID31915254", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C27", "CSC2", "CSC3" ] }, { "n": 28, "citation": "George C, Gontier G, Lacube P et al. The Alzheimer's disease transcriptome mimics the neuroprotective signature of IGF-1 receptor-deficient neurons. Brain : a journal of neurology. 2017.", "tier": "A", "kind": "primary", "pmid": "28595357", "doi": "10.1093/brain/awx132", "url": "https://pubmed.ncbi.nlm.nih.gov/28595357/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "Adult-neuronal-IGF1R-programme", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C28", "CSC2", "CSC3" ] }, { "n": 29, "citation": "Clarke JR, Lyra E Silva NM, Figueiredo CP et al. Alzheimer-associated Aβ oligomers impact the central nervous system to induce peripheral metabolic deregulation. EMBO molecular medicine. 2015.", "tier": "A", "kind": "primary", "pmid": "25617315", "doi": "10.15252/emmm.201404183", "url": "https://pubmed.ncbi.nlm.nih.gov/25617315/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID25617315", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C29", "CSC2", "CSC3" ] }, { "n": 30, "citation": "Cai W, Xue C, Sakaguchi M et al. Insulin regulates astrocyte gliotransmission and modulates behavior. The Journal of clinical investigation. 2018.", "tier": "A", "kind": "primary", "pmid": "29664737", "doi": "10.1172/JCI99366", "url": "https://pubmed.ncbi.nlm.nih.gov/29664737/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID29664737", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C30", "CSC2" ] }, { "n": 31, "citation": "Logan S, Pharaoh GA, Marlin MC et al. Insulin-like growth factor receptor signaling regulates working memory, mitochondrial metabolism, and amyloid-β uptake in astrocytes. Molecular metabolism. 2018.", "tier": "A", "kind": "primary", "pmid": "29398615", "doi": "10.1016/j.molmet.2018.01.013", "url": "https://pubmed.ncbi.nlm.nih.gov/29398615/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID29398615", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C31", "CSC2" ] }, { "n": 32, "citation": "Chen W, Liu X, Muñoz VR et al. Loss of insulin signaling in microglia impairs cellular uptake of Aβ and neuroinflammatory response exacerbating AD-like neuropathology. Proceedings of the National Academy of Sciences of the United States of America. 2025.", "tier": "A", "kind": "primary", "pmid": "40388612", "doi": "10.1073/pnas.2501527122", "url": "https://pubmed.ncbi.nlm.nih.gov/40388612/", "status_flags": [ "UpdateOf: PMID39229221" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID40388612", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C32", "CSC2", "CSC3" ] }, { "n": 33, "citation": "Guo Y, Ma X, Li P et al. High-fat diet induced discrepant peripheral and central nervous systems insulin resistance in APPswe/PS1dE9 and wild-type C57BL/6J mice. Aging. 2020.", "tier": "A", "kind": "primary", "pmid": "33291072", "doi": "10.18632/aging.202262", "url": "https://pubmed.ncbi.nlm.nih.gov/33291072/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID33291072", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C33", "CSC2", "CSC3" ] }, { "n": 34, "citation": "Plaschke K, Kopitz J, Siegelin M et al. Insulin-resistant brain state after intracerebroventricular streptozotocin injection exacerbates Alzheimer-like changes in Tg2576 AbetaPP-overexpressing mice. Journal of Alzheimer's disease : JAD. 2010.", "tier": "A", "kind": "primary", "pmid": "20110613", "doi": "10.3233/JAD-2010-1270", "url": "https://pubmed.ncbi.nlm.nih.gov/20110613/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID20110613", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C34", "CSC2", "CSC3" ] }, { "n": 35, "citation": "Hayashi-Park E, Ozment BN, Griffith CM et al. Experimentally induced diabetes worsens neuropathology, but not learning and memory, in middle aged 3xTg mice. Behavioural brain research. 2017.", "tier": "A", "kind": "primary", "pmid": "27173425", "doi": "10.1016/j.bbr.2016.05.020", "url": "https://pubmed.ncbi.nlm.nih.gov/27173425/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID27173425", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C35", "CSC2", "CSC3" ] }, { "n": 36, "citation": "Barthold D, Gibbons LE, Marcum ZA et al. Alzheimer's Disease-Related Neuropathology Among Patients with Medication Treated Type 2 Diabetes in a Community-Based Autopsy Cohort. Journal of Alzheimer's disease : JAD. 2021.", "tier": "A", "kind": "primary", "pmid": "34420950", "doi": "10.3233/JAD-210059", "url": "https://pubmed.ncbi.nlm.nih.gov/34420950/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID34420950", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C36", "CSC1", "CSC4" ] }, { "n": 37, "citation": "Arvanitakis Z, Capuano AW, Wang HY et al. Brain insulin signaling and cerebrovascular disease in human postmortem brain. Acta neuropathologica communications. 2021.", "tier": "A", "kind": "primary", "pmid": "33858515", "doi": "10.1186/s40478-021-01176-9", "url": "https://pubmed.ncbi.nlm.nih.gov/33858515/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "ROS-150-matched-brains", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C37", "CSC1", "CSC3" ] }, { "n": 38, "citation": "Ott A, Stolk RP, van Harskamp F et al. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology. 1999.", "tier": "A", "kind": "primary", "pmid": "10599761", "doi": "10.1212/wnl.53.9.1937", "url": "https://pubmed.ncbi.nlm.nih.gov/10599761/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID10599761", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C38", "CSC3" ] }, { "n": 39, "citation": "Westwood AJ, Beiser A, Decarli C et al. Insulin-like growth factor-1 and risk of Alzheimer dementia and brain atrophy. Neurology. 2014.", "tier": "A", "kind": "primary", "pmid": "24706014", "doi": "10.1212/WNL.0000000000000382", "url": "https://pubmed.ncbi.nlm.nih.gov/24706014/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID24706014", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C39", "CSC3" ] }, { "n": 40, "citation": "Xu F, Wu S, Gao S et al. Causal association between insulin sensitivity index and Alzheimer's disease. Journal of neurochemistry. 2025.", "tier": "A", "kind": "primary", "pmid": "39479764", "doi": "10.1111/jnc.16254", "url": "https://pubmed.ncbi.nlm.nih.gov/39479764/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID39479764", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C40", "CSC3" ] }, { "n": 41, "citation": "Liu D, Baranova A, Zhang F et al. Evaluating the Causal Effect of Type 2 Diabetes on Alzheimer's Disease Using Large-Scale Genetic Data. The journal of prevention of Alzheimer's disease. 2024.", "tier": "A", "kind": "primary", "pmid": "39350373", "doi": "10.14283/jpad.2024.148", "url": "https://pubmed.ncbi.nlm.nih.gov/39350373/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID39350373", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C41", "CSC3" ] }, { "n": 42, "citation": "Walter S, Marden JR, Kubzansky LD et al. Diabetic Phenotypes and Late-Life Dementia Risk: A Mechanism-specific Mendelian Randomization Study. Alzheimer disease and associated disorders. 2016.", "tier": "A", "kind": "primary", "pmid": "26650880", "doi": "10.1097/WAD.0000000000000128", "url": "https://pubmed.ncbi.nlm.nih.gov/26650880/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID26650880", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C42", "CSC3" ] }, { "n": 43, "citation": "Wang ZJ, Li XR, Chai SF et al. Semaglutide ameliorates cognition and glucose metabolism dysfunction in the 3xTg mouse model of Alzheimer's disease via the GLP-1R/SIRT1/GLUT4 pathway. Neuropharmacology. 2023.", "tier": "A", "kind": "primary", "pmid": "37730113", "doi": "10.1016/j.neuropharm.2023.109716", "url": "https://pubmed.ncbi.nlm.nih.gov/37730113/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID37730113", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C43", "CSC2", "CSC4" ] }, { "n": 44, "citation": "Chen Y, Zhao Y, Dai CL et al. Intranasal insulin restores insulin signaling, increases synaptic proteins, and reduces Aβ level and microglia activation in the brains of 3xTg-AD mice. Experimental neurology. 2014.", "tier": "A", "kind": "primary", "pmid": "24918340", "doi": "10.1016/j.expneurol.2014.06.004", "url": "https://pubmed.ncbi.nlm.nih.gov/24918340/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID24918340", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C44", "CSC2", "CSC4" ] }, { "n": 45, "citation": "Benedict C, Hallschmid M, Hatke A et al. Intranasal insulin improves memory in humans. Psychoneuroendocrinology. 2004.", "tier": "A", "kind": "rct", "pmid": "15288712", "doi": "10.1016/j.psyneuen.2004.04.003", "url": "https://pubmed.ncbi.nlm.nih.gov/15288712/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID15288712", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C45", "CSC2", "CSC4" ] }, { "n": 46, "citation": "Lowe S, Sher E, Wishart G et al. An assessment of the central disposition of intranasally administered insulin lispro in the cerebrospinal fluid of healthy volunteers and beagle dogs. Drug delivery and translational research. 2017.", "tier": "A", "kind": "rct", "pmid": "27553192", "doi": "10.1007/s13346-016-0325-8", "url": "https://pubmed.ncbi.nlm.nih.gov/27553192/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID27553192", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C46", "CSC4" ] }, { "n": 47, "citation": "Sai KKS, Erichsen JM, Gollapelli KK et al. First-in-human positron emission tomography study of intranasal insulin in aging and MCI. Alzheimer's & dementia (New York, N. Y.). 2025.", "tier": "A", "kind": "primary", "pmid": "40703476", "doi": "10.1002/trc2.70123", "url": "https://pubmed.ncbi.nlm.nih.gov/40703476/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID40703476", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C47", "CSC4" ] }, { "n": 48, "citation": "Reger MA, Watson GS, Green PS et al. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology. 2008.", "tier": "A", "kind": "rct", "pmid": "17942819", "doi": "10.1212/01.WNL.0000265401.62434.36", "url": "https://pubmed.ncbi.nlm.nih.gov/17942819/", "status_flags": [ "ErratumIn: PMID not supplied" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID17942819", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C48", "CSC4" ] }, { "n": 49, "citation": "Craft S, Baker LD, Montine TJ et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Archives of neurology. 2012.", "tier": "A", "kind": "rct", "pmid": "21911655", "doi": "10.1001/archneurol.2011.233", "url": "https://pubmed.ncbi.nlm.nih.gov/21911655/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID21911655", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C49", "CSC4" ] }, { "n": 50, "citation": "Claxton A, Baker LD, Hanson A et al. Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer's disease dementia. Journal of Alzheimer's disease : JAD. 2015.", "tier": "A", "kind": "rct", "pmid": "25374101", "doi": "10.3233/JAD-141791", "url": "https://pubmed.ncbi.nlm.nih.gov/25374101/", "status_flags": [ "ErratumIn: PMID25869922" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID25374101", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C50", "CSC4" ] }, { "n": 51, "citation": "Craft S, Claxton A, Baker LD et al. Effects of Regular and Long-Acting Insulin on Cognition and Alzheimer's Disease Biomarkers: A Pilot Clinical Trial. Journal of Alzheimer's disease : JAD. 2017.", "tier": "A", "kind": "rct", "pmid": "28372335", "doi": "10.3233/JAD-161256", "url": "https://pubmed.ncbi.nlm.nih.gov/28372335/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID28372335", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C51", "CSC4" ] }, { "n": 52, "citation": "Rosenbloom M, Barclay TR, Kashyap B et al. A Phase II, Single-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Therapeutic Efficacy of Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease. Drugs & aging. 2021.", "tier": "A", "kind": "rct", "pmid": "33719017", "doi": "10.1007/s40266-021-00845-7", "url": "https://pubmed.ncbi.nlm.nih.gov/33719017/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID33719017", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C52", "CSC4" ] }, { "n": 53, "citation": "Craft S, Raman R, Chow TW et al. Safety, Efficacy, and Feasibility of Intranasal Insulin for the Treatment of Mild Cognitive Impairment and Alzheimer Disease Dementia: A Randomized Clinical Trial. JAMA neurology. 2020.", "tier": "A", "kind": "rct", "pmid": "32568367", "doi": "10.1001/jamaneurol.2020.1840", "url": "https://pubmed.ncbi.nlm.nih.gov/32568367/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "SNIFF-NCT01767909", "access_depth": "full_text_partial", "access_note": "Complete primary abstract and linked-status metadata examined. Selected body sections: Methods:Participants, Statistical Analysis; Results:CSF, Secondary Analyses. No complete-paper or supplement audit claimed.", "carries_claims": [ "C53", "CSC4", "CH" ] }, { "n": 54, "citation": "Kellar D, Lockhart SN, Aisen P et al. Intranasal Insulin Reduces White Matter Hyperintensity Progression in Association with Improvements in Cognition and CSF Biomarker Profiles in Mild Cognitive Impairment and Alzheimer's Disease. The journal of prevention of Alzheimer's disease. 2021.", "tier": "A", "kind": "rct", "pmid": "34101779", "doi": "10.14283/jpad.2021.14", "url": "https://pubmed.ncbi.nlm.nih.gov/34101779/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "SNIFF-NCT01767909", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C54", "CSC4" ] }, { "n": 55, "citation": "Kellar D, Register T, Lockhart SN et al. Intranasal insulin modulates cerebrospinal fluid markers of neuroinflammation in mild cognitive impairment and Alzheimer's disease: a randomized trial. Scientific reports. 2022.", "tier": "A", "kind": "rct", "pmid": "35079029", "doi": "10.1038/s41598-022-05165-3", "url": "https://pubmed.ncbi.nlm.nih.gov/35079029/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "SNIFF-NCT01767909", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C55", "CSC4" ] }, { "n": 56, "citation": "Gejl M, Gjedde A, Egefjord L et al. In Alzheimer's Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial. Frontiers in aging neuroscience. 2016.", "tier": "A", "kind": "primary", "pmid": "27252647", "doi": "10.3389/fnagi.2016.00108", "url": "https://pubmed.ncbi.nlm.nih.gov/27252647/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "Liraglutide-NCT01469351", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C56", "CSC4" ] }, { "n": 57, "citation": "Gejl M, Brock B, Egefjord L et al. Blood-Brain Glucose Transfer in Alzheimer's disease: Effect of GLP-1 Analog Treatment. Scientific reports. 2017.", "tier": "A", "kind": "rct", "pmid": "29235507", "doi": "10.1038/s41598-017-17718-y", "url": "https://pubmed.ncbi.nlm.nih.gov/29235507/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "Liraglutide-NCT01469351", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C57", "CSC4" ] }, { "n": 58, "citation": "Edison P, Femminella GD, Ritchie C et al. Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trial. Nature medicine. 2026.", "tier": "A", "kind": "rct", "pmid": "41326666", "doi": "10.1038/s41591-025-04106-7", "url": "https://pubmed.ncbi.nlm.nih.gov/41326666/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID41326666", "access_depth": "full_text_partial", "access_note": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Results:paragraph0, 1:Results:paragraph15, 1:Results:paragraph17, 1:Results:paragraph19, 1:Results:paragraph20, 1:Results:paragraph22, 1:Results:paragraph24, 3:Methods:paragraph1, 3:Methods:paragraph3, 3:Methods:paragraph5, 3:Methods:paragraph6, 3:Methods:paragraph10, 3:Methods:paragraph12, 3:Methods:paragraph63, 3:Methods:paragraph65, 3:Methods:paragraph66. No complete-paper or supplement audit claimed.", "carries_claims": [ "C58", "CSC4", "CH" ] }, { "n": 59, "citation": "Mullins RJ, Mustapic M, Chia CW et al. A Pilot Study of Exenatide Actions in Alzheimer's Disease. Current Alzheimer research. 2019.", "tier": "A", "kind": "rct", "pmid": "31518224", "doi": "10.2174/1567205016666190913155950", "url": "https://pubmed.ncbi.nlm.nih.gov/31518224/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID31518224", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C59", "CSC4" ] }, { "n": 60, "citation": "Dei Cas A, Micheli MM, Aldigeri R et al. Long-acting exenatide does not prevent cognitive decline in mild cognitive impairment: a proof-of-concept clinical trial. Journal of endocrinological investigation. 2024.", "tier": "A", "kind": "rct", "pmid": "38565814", "doi": "10.1007/s40618-024-02320-7", "url": "https://pubmed.ncbi.nlm.nih.gov/38565814/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID38565814", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C60", "CSC4" ] }, { "n": 61, "citation": "Cummings JL, Atri A, Sano M et al. Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials. Lancet (London, England). 2026.", "tier": "A", "kind": "rct", "pmid": "41865758", "doi": "10.1016/S0140-6736(26)00459-9", "url": "https://pubmed.ncbi.nlm.nih.gov/41865758/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID41865758", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C61", "CSC4", "CH" ] }, { "n": 62, "citation": "Wang W, Wang Q, Qi X et al. Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2024.", "tier": "A", "kind": "primary", "pmid": "39445596", "doi": "10.1002/alz.14313", "url": "https://pubmed.ncbi.nlm.nih.gov/39445596/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID39445596", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C62", "CSC3", "CSC4" ] }, { "n": 63, "citation": "Nørgaard CH, Friedrich S, Hansen CT et al. Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers. Alzheimer's & dementia (New York, N. Y.). 2022.", "tier": "A", "kind": "primary", "pmid": "35229024", "doi": "10.1002/trc2.12268", "url": "https://pubmed.ncbi.nlm.nih.gov/35229024/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID35229024", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C63", "CSC3", "CSC4" ] }, { "n": 64, "citation": "Gold M, Alderton C, Zvartau-Hind M et al. Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study. Dementia and geriatric cognitive disorders. 2010.", "tier": "A", "kind": "rct", "pmid": "20733306", "doi": "10.1159/000318845", "url": "https://pubmed.ncbi.nlm.nih.gov/20733306/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID20733306", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C64", "CSC4" ] }, { "n": 65, "citation": "Harrington C, Sawchak S, Chiang C et al. Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies. Current Alzheimer research. 2011.", "tier": "A", "kind": "rct", "pmid": "21592048", "doi": "10.2174/156720511796391935", "url": "https://pubmed.ncbi.nlm.nih.gov/21592048/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID21592048", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C65", "CSC4" ] }, { "n": 66, "citation": "Burns DK, Alexander RC, Welsh-Bohmer KA et al. Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Neurology. 2021.", "tier": "A", "kind": "rct", "pmid": "34146512", "doi": "10.1016/S1474-4422(21)00043-0", "url": "https://pubmed.ncbi.nlm.nih.gov/34146512/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID34146512", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C66", "CSC3", "CSC4" ] }, { "n": 67, "citation": "Luchsinger JA, Perez T, Chang H et al. Metformin in Amnestic Mild Cognitive Impairment: Results of a Pilot Randomized Placebo Controlled Clinical Trial. Journal of Alzheimer's disease : JAD. 2016.", "tier": "A", "kind": "rct", "pmid": "26890736", "doi": "10.3233/JAD-150493", "url": "https://pubmed.ncbi.nlm.nih.gov/26890736/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID26890736", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C67", "CSC4" ] }, { "n": 68, "citation": "Erichsen JM, Register TC, Sutphen C et al. A phase 2A/B randomized trial of metabolic modulators intranasal insulin and empagliflozin for MCI and early AD. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2025.", "tier": "A", "kind": "rct", "pmid": "41057918", "doi": "10.1002/alz.70704", "url": "https://pubmed.ncbi.nlm.nih.gov/41057918/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID41057918", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C68", "CSC4" ] } ], "independence_basis": { "required": false, "lines": [ { "label": "Functional tissue versus biomarker validation", "sources": [ 2, 3, 11, 12 ], "excludes_error": "Ex-vivo responses and orthogonal EV methods exclude different assay errors; postmortem timing and sample overlap remain." }, { "label": "Adult/cell and branch genetic contrasts", "sources": [ 16, 31, 32, 13 ], "excludes_error": "Distinguish developmental, neuronal, glial, IR and IGF explanations, though disease transgenes and mouse backgrounds constrain generality." }, { "label": "Genetic/population exposure instruments", "sources": [ 40, 41, 42, 63 ], "excludes_error": "Reduce conventional exposure confounding but do not isolate a neuronal initiating mediator." }, { "label": "Randomized clinical regimen contrasts", "sources": [ 53, 58, 61, 65, 66 ], "excludes_error": "Separate treatment assignment from indication bias while CNS engagement, timing and drug specificity remain." } ], "shared_failure_mode_checked": true, "note": "68 reports are not 68 independent causal lines. ROS150, SNIFF device1 follow-ups, one liraglutide trial reanalysis, NIRKO and adult IGF programmes and shared GWAS are identified. EVOKE and REFLECT each report two trials but count once as a primary report. Orthogonal directions expose distinct errors without proving a common neuronal mechanism." }, "consensus_validation": { "completed": true, "status": "documented_historical_discovery_and_reconciliation", "provider": "Consensus", "provider_mode": "Historical browser/connector use as recorded in the source artifacts", "local_audit_date": "2026-10-09", "primary_comparison_count": null, "reported_usage": [], "grade_changed": false, "score_before": { "hsef_level": "Γ", "hsef_descriptor": "Mechanistically plausible, partial system support", "confidence": "Moderate", "confidence_rationale": "68 primary reports with 6 selected partial-body examinations; density, heterogeneous controls and incomplete access set the confidence, not correctness.", "rests_on_non_peer_reviewed_work": false, "rationale": "Γ follows the preregistered weakest-link bundle (Γ,Ε,Γ,Γ); primary-SC3 and scope-matched sensitivities also return Γ. Model-specific causal contribution earns Ε, while primary sporadic neuronal initiation and clinically proven correction remain unestablished. Functional tissue resistance, acute memory effects, peripheral prevention and FDG changes are kept distinct. Positive models and valid human causal equivalents are assessed together, without automatically re-capping their weaker observational members." }, "score_after": { "hsef_level": "Γ", "hsef_descriptor": "Mechanistically plausible, partial system support", "confidence": "Moderate", "confidence_rationale": "68 primary reports with 6 selected partial-body examinations; density, heterogeneous controls and incomplete access set the confidence, not correctness.", "rests_on_non_peer_reviewed_work": false, "rationale": "Γ follows the preregistered weakest-link bundle (Γ,Ε,Γ,Γ); primary-SC3 and scope-matched sensitivities also return Γ. Model-specific causal contribution earns Ε, while primary sporadic neuronal initiation and clinically proven correction remain unestablished. Functional tissue resistance, acute memory effects, peripheral prevention and FDG changes are kept distinct. Positive models and valid human causal equivalents are assessed together, without automatically re-capping their weaker observational members." }, "independent_blinded_audit": false, "raw_receipts": [ { "path": "deliverables\\hsef_v53_popularity_ranks_16_20_2026-10-05\\type3-diabetes-alz\\consensus\\browser-proof.png", "sha256": "33f3485f8c0f61618a4a90446f64fe6f174491ae3ea9be86fbdb899dcd4bbe2a" }, { "path": "deliverables\\hsef_v53_popularity_ranks_16_20_2026-10-05\\type3-diabetes-alz\\consensus\\discovery-dom.txt", "sha256": "f5a795160fa8d30fd4c81a51c168a5db3de13c577b33990b9e8fbbfbc1f66fc0" }, { "path": "deliverables\\hsef_v53_popularity_ranks_16_20_2026-10-05\\type3-diabetes-alz\\consensus\\discovery-response.txt", "sha256": "47f66bbbb1e44e2cce58df3dc2dee921321c3ce8bddd6db3a549e12e7e0f615b" }, { "path": "deliverables\\hsef_v53_popularity_ranks_16_20_2026-10-05\\type3-diabetes-alz\\consensus\\followup-dom.txt", "sha256": "0cb25b6f400479e4f235a2d49f151252b1e5444c4498cec3f4e170b32d5abb21" }, { "path": "deliverables\\hsef_v53_popularity_ranks_16_20_2026-10-05\\type3-diabetes-alz\\consensus\\followup-response.txt", "sha256": "81ae0d17894681d95a3c32bf8b5bd01556dc72ee314ee95bffb9e67994d7bc7c" } ], "limitations": "This verifies documented historical use and links the record to the final edition. It adds no primary-source, full-text, independence or verification credit. Original access remains limited to the source-specific record." } }